

**UNIT VIII. DETERMINATION OF SEX OF ORIGIN,  
NONGENETIC MARKERS AND BLOOD COMPONENT PROFILING**

## SECTION 49. DETERMINATION OF SEX OF ORIGIN

### 49.1 Introduction

For some years, there has been interest in developing procedures which would enable the reliable determination of sex of origin of bloodstains and of certain other human tissues such as saliva and hairs. In some cases, such a determination could be informative and useful. Three general approaches have been used for this purpose, two of them cytological, and the third having to do with the measurement of sex hormone levels. The cytological techniques are concerned with the determination of either sex chromatin (Barr bodies), or of so-called F-bodies (Y-bodies) in cells.

### 49.2 Determination of Sex Chromatin

Sex chromatin bodies (Barr bodies) were discussed in section 1.2.4.4. These structures are characteristic of nuclei in certain cells from female mammals, including the nuclei of smooth muscle, adrenal cortex, and various epidermal cells. The structures may also be seen in polymorphonuclear leucocytes from peripheral blood smears of females, where they are sometimes called "drumsticks". These structures were first observed in cat neurons (Barr and Bertrand, 1949), and later in other cells and other species (Barr, 1957 and 1960). The nature of sex chromatin in cells is discussed by Moore (1966a), and he has also described its discovery and the earlier work in the field (Moore, 1966b). Davidson and Smith (1954) first noted sex chromatin structures ("drumsticks") in the neutrophil leucocytes of peripheral blood from females. These structures should be called "sex chromatin", or "X chromatin", though the latter term has not gained wide acceptance. Dr. Barr himself has discouraged the use of the term "Barr bodies".

Reports on the frequency of sex chromatin have varied, depending upon the tissue being studied. At least 100 cells must be examined according to most authorities, and some have recommended from 300 to 500. The variations may be due to tissue differences, and to differences in various technical factors. Other nuclear appendages may be mistaken for sex chromatin bodies by inexperienced observers as well. The somewhat subjective nature of sex chromatin determinations has been noted by Grob and Kupperman (1961), and they emphasized the importance of using reproducible techniques and experienced scorers.

In the earlier literature, a low frequency of occurrence of sex chromatin bodies was reported in cells from normal human males, but the general consensus of opinion some years ago seemed to be that normal male cells do not in fact exhibit the structures (Grob and Kupperman, 1961). As was noted earlier, there is evidence (Ohno, 1966) that the sex chromatin body structure represents an inactivated X chromosome (see in section 1.2.4.4). Thus, in people suffering

from abnormalities of sex chromosome composition, the correlation between phenotypic sex and sex chromatin body frequency in nuclei may not hold up. These cases are comparatively rare in the population, but could lead to misinterpretation in medicolegal work. Discrepancies between phenotypic sex and chromatin body frequency may be observed in (1) chromatin negative females; (2) chromatin positive males; and (3) genetic mosaics. Phenotypic females who are chromatin negative are mainly of two types, those with Turner's syndrome, and those with testicular feminization syndrome. The former have various abnormalities, including ovarian agenesis, and karyotype analysis reveals that they have only 45 chromosomes, the missing one being an X. They are sometimes called "XO females". The latter group are phenotypically female, although they exhibit various abnormalities of sexual development. Karyotype analysis shows that they are chromosomally male, i.e., that they are XY and have 46 chromosomes. They are sometimes called "XY females". Males who are chromatin positive are often those who have so-called Klinefelter's syndrome. They have 47 chromosomes and an XXY sex chromosome composition, and they show a variety of abnormalities of sexual development. Genetic mosaics may be of either phenotypic sex, and different tissues of the same individual may show differences in sex chromatin pattern. Cytologic sexing by means of chromatin bodies has been reviewed by Grob (1970).

#### 49.2.1 Sex chromatin determination in blood and bloodstains

Postmortem blood does not appear to be very suitable for sex chromatin determination, apparently because the leucocytes undergo lysis and degradative changes quite soon after death. Dixon and Torr (1956 and 1957) said that they had had no success with this technique in post mortem blood. Schilling (1960) reported that post mortem blood was good for up to about 6 hours after death for this determination.

Some reports have indicated limited success with bloodstains. De Bernardi (1959) studied bloodstains on hairs with some success. He said that at least 200 nuclei needed to be examined. Davidson (1963) described a procedure for the isolation of white cells from bloodstains, and examined a number of slides for chromatin bodies. Diagnosis of sex could not be made in every case, and he thought that the results of the determination should be taken only as an indication of possible sex. Ishizu *et al.* (1973) suggested that chromatin body determinations coupled with F-body determinations (see below) on the same material provided a more definitive conclusion than either cytological method by

itself. Caroff and Breton (1966) reviewed chromatin body sexing from a medicolegal point of view.

#### 49.2.2 Sex chromatin determination in epithelial cells and hair

From a forensic point of view, the ability to determine sex in epithelial cells is probably most applicable to post mortem tissues and to exfoliated epithelial cells in saliva stains and traces. Dixon and Torr (1956 and 1957) noted that chromatin bodies could survive for a few weeks in post mortem epithelial tissues, and thought that this determination might be of value in some cases, such as for example with a body part which had been recovered and submitted for identification. They buried fetal tissue from a female in soil, and could still determine sex chromatin for about 4 weeks. Holzer and Marberger (1957) obtained somewhat similar results in their tests on post mortem tissues. Edwards and Cameron (1964) said that excellent preparations could be obtained from the mucosal epithelium of the urinary bladder, but that bodies even a few days old could give misleading results.

Sanderson and Stewart (1961) described a rapid, easy method for sex chromatin determination in buccal epithelial cells using aceto-orcein staining. Radam (1965) discussed the preparation of buccal epithelial cells for chromatin body determination. Renard (1971) described techniques for the preparation of epithelial cells from salivary and vaginal materials and for chromatin body determinations. Generally, 40% of the nuclei of cells of female origin recovered from various stains were chromatin positive. Ando (1973) examined buccal epithelial cells from salivary stains and traces for both Barr bodies and F-bodies (see below). The chromatin bodies were found to be less stable over the course of time than the F-bodies.

Hair root sheath cells have been found to be suitable material for chromatin body sex determinations in many cases. Dixon and Torr (1956) found that hair root sheath cells provided excellent material in post mortem examinations. Schmid (1967) described a technique for sexing single head hairs from living persons. It was best if the hairs were examined at once, and not stored, in his experiments. Culbertson *et al.* (1969) also obtained reliable determinations from hair root sheath cells. In 30 people, 15 males and 15 females, Montanari *et al.* (1967) found that Barr bodies occurred in  $29 \pm 5\%$  of the nuclei of these cells from females, while the values were very much lower in preparations from males ( $6 \pm 2\%$ ). Bassett (1978) described procedures for sex chromatin determination in hair root sheath cells, and reported generally reliable and satisfactory results. He noted the importance of having experienced examiners score the nuclei, and the possibility of subjective error. He said further that preparations with sex chromatin frequency in the range of 10 to 40% of scorable nuclei should be considered inconclusive. Males and females showed sex chromatin in 5% and 57%, respectively, of their scorable nuclei.

Moore (1966c) discussed the determination of sex chromatin in connection with medicolegal problems.

### 49.3 Y-Body (F-Body) Determinations

In 1968, Caspersson *et al.* reported that metaphase chromosomes exhibited various fluorescence patterns after staining with fluorescent dyes, and it was suggested that the technique might provide a useful tool for chromosome mapping. These experiments were done on nonhuman material. Certain loci of the chromosomes were observed to bind quinacrine diHCl preferentially. In 1969, Zech found that the long arm of the human Y chromosome fluoresced brightly after staining human chromosome preparations with quinacrine mustards. The ability to observe a small fluorescent body in human cell preparations containing a Y chromosome, after staining with quinacrine diHCl, was quickly shown to be a property of a number of types of cells. In buccal epithelium, leucocytes and cultured skin fibroblasts, a large proportion of the cells from males (usually 25–50%) exhibited the fluorescent body (or F-body) after suitable preparation and quinacrine di-HCl staining (Pearson *et al.*, 1970; George, 1970).

#### 49.3.1 F-Body determinations in dried blood and bloodstains

The current of opinion in the literature appears to be that F-body determinations can provide a highly reliable method of dried blood sexing if the procedures are carried out skillfully and if a sufficiently large number of leucocytes can be obtained for counting. A number of different techniques have been reported for these determinations. There is some variation in the estimate of the maximum age of a bloodstain that is still suitable for sexing by F-body counting. In addition, storage temperature and conditions as well as the nature of the substratum appear to affect the results obtained.

Phillips and Gaten (1971) reported successful results with bloodstains up to 10 days old on solid (nonabsorbent) substrata. About 86% of the leucocytes from male blood smears showed F-bodies, while the figure was only about 0.5% with female samples. In 1972, Phillips and Webster gave an improved technique in which 2 mM MgCl<sub>2</sub> was employed as an extraction medium instead of McIlvaine's buffer. In 1974, Phillips and Gitsham gave a procedure for bloodstains on absorbent substrata, and reported the results of a series of blind trial studies. Extraction techniques were not found very satisfactory for F-body determinations. Scraping the stain so as to cause a "dust" of bloodstain to fall upon the slide was the preferred technique. Reliable sexing was not possible in all the stains tested, but could be done in many cases. At least 100 nuclei had to be scored, they said. It was important to recognize, too, that readers had to become experienced in examining these preparations, and that there was an element of subjectivity in the determination. Müller *et al.* (1971) tested stains up to 32 days old and always found a higher F-body score in male bloods than in female bloods.

Schwinger (1972) could detect F-bodies in stains up to 30 days old. Blažek and Bráza (1972a) were able to determine the sex of bloodstains by F-body technique in stains 32 days

old. They said that the decay in the percentage of F-body positive nuclei from male stains was not a linear function of stain age. Aragonés and Egozcue (1973) described a method which was applicable to stains up to 90 days old on absorbent or nonabsorbent surfaces. Brinkmann and Jobst (1973) found that 12.5% to 50% of cells from male bloodstains up to 4 weeks old contained F-bodies. It was possible to diagnose stains stored for 28 months at room temperature as being of male origin. Ishizu (1973) reported finding from 49% to 88% F-body-containing cells in blood smears from males and only 0% to 4% in those from females. Similar results were obtained with blood smears from newborns, and with cord bloods. Blood smears up to 5 months old from males showed more than 30% F-body positive cells. Schaidt and Krüger (1973) found that blood smears could be sexed by F-body technique for up to 19 days when kept at room temperature, but for up to 63 weeks if kept in a refrigerator. Bloodstains on textiles could be sexed for 8 weeks. Tröger and Liebhart (1974) found that male bloodstains stored for up to 15 months still showed detectable F-bodies. Thomsen (1975) gave an improved procedure for F-body determinations, the improvement consisting of a more effective filter combination for the fluorescence microscope.

Kringsholm *et al.* (1976) noted that they had found no overlapping between the sexes in the percentage of cells showing F-bodies. The highest female counts were always lower than the lowest male counts. They had not, therefore, observed any "false positive" males. Occasionally, a male blood could give a deceptively low F-body count, however, and this situation would result in a "false negative". A low F-body count had to be interpreted with caution, therefore, and could mean (1) a stain of female origin; (2) an older stain that was of male origin; or (3) a stain of male origin from a male with an abnormally low percentage of F-body positive cells. Kringsholm *et al.* (1977) found that most bloodstains stored at room temperature for up to 21 weeks could be sexed by F-body technique. They did observe a few false negative results. Thomsen (1978) extended these aging studies to include stains kept at 5° and at 55°. False negative results appeared earlier in stains kept at either of these two temperatures than in those kept at room temperature, but there were no false positives. It appeared, therefore, that bloodstains retain their Y-body counts better at room temperature than at 5°, while the opposite appeared to be the case in the studies of blood smears (Schaidt and Krüger, 1973).

Schwinger and Tröger (1977) carried out blind trial studies using two different, independent scorers. In 21 stains up to 4 months old, the results of the two readers were very similar. Nanko (1980) has noted that F-body count in male blood smears fixed in methanol declines over the course of time, but the reason for the decline was not clear.

Wigmore *et al.* (1979a) reported on their technique for F-body determination in stains and on a series of blind trial sexing experiments. The subjective nature of the technique was emphasized, and the importance of carrying out case sample and control examinations on a "blind" basis was

stressed. Cotton was found to be a problematical substratum for bloodstains for this procedure, when compared with glass or nylon. It was difficult to obtain good results from bloodstains on wood or leather as well. In contrast to other reports, there was no significant reduction in the Y index of bloodstains as a function of age up to 138 days. In blind trial studies on casework materials, 65% of male bloodstains could be correctly identified, while no stains of female origin were misidentified as being male. Similar blind trial studies, with similar results, were reported by Wigmore *et al.* (1979b).

Thomsen (1979) gave a brief review of bloodstain sexing by F-body technique, and said that it provided a useful technique in bloodstain analysis.

Curran (1976) reviewed a trial court case in New York in which opposing panels of experts disagreed over whether a bloodstain on a jacket could be reliably sexed by cytological techniques. The stain was about 22 months old when the tests were conducted. The trial court judge in this case held that the tests to determine the sexual origin of cells in the stain (sex chromatin and F-body) failed to meet the requirements for reliability and general scientific acceptance, and the testimony was not admitted.

#### 49.3.2 F-Body determinations in other tissues

There are a number of reports on sex determination by F-body technique in hair root cells (Sakai, 1972; Ishizu, 1972; Brinkmann and Jobst, 1973; Tröger and Liebhart, 1974; Kringsholm *et al.*, 1977). Tröger and Liebhart (1974) found that hair root sheath cells were suitable only for up to about 5 days with stored hairs, but Ishizu (1972) reported successful results with hairs up to 150 days old, as did Kringsholm *et al.* (1977) with hairs up to 27 weeks old. Nagamori (1978) reported successful F-body sexing determinations in hairs without roots up to 4 weeks old, provided they were kept dry.

Cells from various tissues and organs, examined post mortem, have been found suitable for F-body sexing determination. Kovacs *et al.* (1972) obtained reliable results in looking at 100 cells from brain, heart, liver, spleen and bone marrow in 16 male and 10 female bodies. Blažek and Bráza (1972b) obtained similar results with various tissues, and they showed further (1972c) that another fluorescent dye called 1-[(6-chloro-2-methoxy-9-acridinyl)amino]-3-(dimethylamino)-2-propanol diHCl worked as well as quina-crine diHCl. F-body determination has also been described in the cells of cartilage, periosteum and marrow (Berghaus *et al.*, 1973) and in human tooth pulp (Sommermater, 1975).

Tröger *et al.* (1976) found that Y-bodies were detectable in significant percentages in buccal epithelial cells derived from cigarette butts smoked by males. 10% of the male cells still showed Y-bodies when the cigarette butts were 43 days old, while the female cells from the same source had never shown counts higher than 6%. Y-bodies can be detected in sperm cells (Sakai, 1972). Tröger and Eisenmenger (1977) did F-body analysis in vaginal epithelium to try and use their absence as a means of identifying the cells as being of female

origin. They said that stains had to be less than 4 weeks old, however, to justify such a conclusion.

Ishizu *et al.* (1973) described a technique for the consecutive determination of F-bodies and sex chromatin in the same sample material, which included saliva, hair roots and blood. The results of the two determinations, they said, were more definitive than those from either separate determination alone.

#### 49.4 Sex Hormone Level Determinations

The use of pregnancy-associated hormones as bloodstain markers for blood derived from pregnant women was discussed in section 8.2.1. The idea of using male and female sex hormones (primarily testosterone and  $17\beta$ -estradiol) as indicators of sex in dried bloodstains has been around for some years, but there appear to be very few published systematic studies on the subject. Among the most sensitive (and, hence, desirable for this purpose) methods of the assay of lower MW compounds such as steroids in complex mixtures is radioimmunoassay (RIA). This technique was discussed briefly in section 1.3.4.3.

Many RIA procedures have been described for steroid hormones, like testosterone, in serum (see, for example, Sheldon and Coppenger, 1977; Joshi *et al.*, 1979). In theory, these procedures should be adaptable to the analysis of bloodstains, and one could try to relate the sex of origin of bloodstains to the levels of one or a combination of the major sex hormones, especially testosterone,  $17\beta$ -estradiol and progesterone.

The most extensive studies to date are those of Shaler (1975). He adapted serum RIA procedures for testosterone (T) and estradiol (E) to determinations in bloodstains, and then measured the "T/E" ratios in a selection of samples. The ratio was first determined on a "blind" basis in about

1,500 serum samples. The T/E ratio varied from 60 to 0.02. Analysis showed that values greater than 3.51 could be assigned as male with a high degree of probability. Predictability of sex based on the T/E was not 100% accurate, however; several male sera showed abnormally low ratios and several female sera showed abnormally high values. Unfortunately, nothing was known about the history or state of health of the donors. The ratio was next determined in about 250 bloodstains from 6 to 8 months old. Sex of origin was known, but the hormone level measurements were carried out on a blind trial basis. The predictability of sex was about the same as that found for the serum samples. It was noted that in the bloodstains, the T/E ratio separating males from females at the same probability level was 1.0, rather than the 3.51 seen with the serum samples. 98.9% of bloodstains from males had T/E ratios greater than 2.0, while 92.7% of stains of female origin had values below 1.0.

Recently, Szendrőnyi and Földes (1980) reported that they could successfully sex experimental bloodstains up to 6 weeks old by determining the testosterone concentration by RIA. Stains prepared from 32 males and 24 females were studied, and showed little change in testosterone concentration between 48 hours and 6 weeks of aging. The protein concentration of the samples was also determined, and it was recommended that the testosterone level be referred to the protein concentration when analyzing stains. Thus, testosterone levels expressed as pg/10 mg protein in stains correctly predicted the sex of origin in all cases in the limited number of stains analyzed.

Other hormones have been assayed in dried blood by RIA, but not for medicolegal purposes. Illig and Rodriguez de Vera Roda (1976) reported on an RIA technique for determining thyroid stimulating hormone (TSH) in dried blood spots. The method was apparently designed in order to enable samples from newborns to be forwarded to a distant testing laboratory in a convenient way.

## SECTION 50. NON-GENETIC MARKERS AND BLOOD COMPONENT PROFILING

### 50.1 Introduction

Over the years there has been occasional interest in attempting to individualize blood using non-genetically determined components. Three general classes of components have been studied: (1) Components present in blood as the result of environmental exposures or of the ingestion of specific agents. This class includes primarily antibodies and drugs. The antibodies may be directed against blood group antigens, against specific pathogenic agents to which the individual has been exposed, or to allergens. This class also includes the hepatitis antigens. (2) Components present in blood as the result of normal metabolism processes. This class includes primarily metal ions and smaller MW metabolites. And (3) The serum proteins. Although serum proteins are genetically determined, and many are controlled by polymorphic loci, the kinds of studies being discussed here usually seek to find individual differences in the qualitative or quantitative patterns of a large series of the proteins.

Two general approaches have been taken in these studies. In the first, a specific antigen, antibody, drug or component is detected and/or quantitated. In the second, the pattern of a series of components (usually serum proteins) in different individuals is examined. The individual components are not necessarily identified. Quantitative immunoelectrophoretic techniques have been employed in a number of these kinds of studies.

A number of different factors are involved in determining whether non-genetic markers and blood component profiles are truly individualizing markers. In the case of specific blood components, these include: (1) whether the presence and/or quantity of the component is constant in an individual over time, and over what length of time; (2) whether the presence and/or quantity of the component is detectable in dried bloodstains in a way that can be related to a whole blood sample; (3) the extent to which the presence or quantity of the component declines in dried bloodstains over time; and (4) what fraction of the population might be expected to exhibit the presence and/or quantity of the component detected. In the case of blood component profiles, there are similar considerations: (1) whether inter-individual differences exceed intra-individual differences at a given time, and over the course of time; (2) whether patterns in bloodstains accurately reflect the pattern in whole blood from which the stain was derived; and (3) to what extent the different patterns actually vary in a population. Work on non-genetic markers is, for the most part, at an early stage of development in this field. Additional studies will be needed to establish the individualizing value of many of the markers. There is not much doubt that the finding of

certain specific non-genetic markers, such as HBsAg for example, in a bloodstain would be valuable in an investigation, and could prove helpful if a comparison were possible with the blood of the suspected depositor of the stain soon afterwards.

### 50.2 Detection of Specific Components of Blood

#### 50.2.1 Antibodies

Among the first studies on the detection of specific antibodies in dried bloodstains are those of Kirk and his collaborators in the early 1960's. In 1963, Thornton and Kirk conducted studies on the detection of incomplete (Coombs reactive) anti-D in dried bloodstains up to 28 days old. They found that the antibody was detectable, and that it persisted for at least several weeks in dried bloodstains was judged by its titer against Rh+ type O cells. Leister and Kirk (1963) reported on the detection of rheumatoid arthritis factor in dried bloodstains using gamma-globulin treated latex particles as a detection system. Dried, powdered blood kept in vials was used for these experiments. They found that the factor was detectable in dried blood up to 150 days old, and that blood with an initially high titer tended to retain its activity in the dried state. The relationship of the factor being tested for in these studies to the Gm system (section 44) is not altogether clear. In 1964, Leister *et al.* reported a series of experiments on the detection of syphilis antibodies in dried blood. A microflocculation test (Kirk and Bennett, 1939) was used in these studies. 520 dried blood samples up to 140 days old were tested, and the loss of activity was greatest in the first five days. Not every sample retained activity equally well, but a higher percentage of initially strongly reacting samples gave positive results after 140 days than of samples which had reacted more weakly at the beginning.

More recently, King, Whitehead and Werrett have done studies on the detection of various antiparasitic and allergen-associated antibodies in bloodstains. King (1974a) and King *et al.* (1975) described the detection of antibodies to *Mycobacterium tuberculosis*, *Treponema pallidum* (non-specific "syphilis"), *Vibrio cholera* (cholera), *Toxoplasma gondii* (toxoplasmosis), *Trichomonas vaginalis* (trichomoniasis), *Candida albicans* (candidiasis) and *Toxocara canis* (toxocariasis). There were technical difficulties with the *Toxoplasma* and *Toxocara*. Approximately 75 bloodstains were tested with the other five antigens using an indirect fluorescent antibody technique. The majority of samples gave consistent positive and negative results in

separate readings, but some gave ambiguous results. The antibodies were stable in bloodstains for at least several months. In the sample of bloods studied, the discriminating power for the five antigens was calculated to be 0.71, roughly comparable to the ABO blood group system. Antibodies to *Mycobacterium tuberculosis* could be demonstrated in semen if it was not more dilute than 1:10. It was noted that the antibody titer in a positive group of bloods behaves as a continuous variable, and that scoring samples as "positive" or "negative" was an oversimplification. It was also noted, however, that the procedure lends itself to the profiling of a large number of different antigens to which antibodies might be expected. In interpreting the results, caution must be exercised because there are some cross reactions with related antibodies in a large series.

In 1976, Werrett *et al.* extended the antibody profiling studies to include allergen-associated antibodies. These antibodies are of the IgE class (section 1.3.3.2), and require very sensitive detection techniques because the circulating levels of IgE are very low compared to most other serum proteins (see in section 39). Commercially available RIA test kits for four allergens were used in the studies to detect the antibodies in experimentally prepared bloodstains. It was found that the antibodies could be detected in bloodstains on a variety of substrata, but that antibody activity declined more or less linearly to about 50% after 6 weeks. Using the four allergen-associated antibodies, it was possible to discriminate six different blood stains on a blind trial basis, and the results correlated with the reported allergic conditions of the donors. The results were considered to be preliminary but promising, since the range of different antibodies which one assumes could be detected in bloodstains (and for which reagents are available) is quite large.

King *et al.* (1976) reviewed the studies on antibody profiling of bloodstains. The promise and potential value of this approach were discussed. A large number of antimicrobial and allergen-associated antibodies could potentially be employed for this kind of profiling. An antimicrobial antibody profile reflects an individual's environmental exposure and vaccination history. The blood of full-grown adults can be differentiated from that of younger children in this way (King and Whitehead, 1975). In addition, menstrual blood was found to have a much higher antibody level relative to hemoglobin than the circulating blood of the same donor. Allergen antibody profiles could give information about the geographical origins or history of an individual. Information of potential value to an investigation might thus be provided from the examination of a bloodstain at a crime scene.

#### 50.2.2 Drugs and plasma metabolites

The same kind of RIA techniques used to detect drugs in serum can be adapted for measuring drug levels in bloodstains. As noted in section 49.4, Shaler and his collaborators adapted RIA techniques for steroid hormone determination to bloodstain analysis. They have extended these studies to include the detection of a number of drugs as well. Shaler (1975) said that dilantin, a drug used to treat epilepsy, could

be detected in a fragment of bloodstain equivalent to 10  $\mu$ l of blood, and that this represented an amount approximately 100 times larger than what was needed for detection. This work has since been extended to include detection of morphine (Mortimer *et al.*, 1978a; Smith *et al.*, 1980), digoxin (Mortimer *et al.*, 1978b), and barbiturates (Smith, 1980) in bloodstains.

King (1974b) examined the possibility of profiling a series of plasma constituents of clinical importance in the individualization of bloodstains. Data on the levels of  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Cl}^-$ ,  $\text{Ca}^{++}$ ,  $\text{Mg}^{++}$ ,  $\text{PO}_4^{3-}$ , protein, albumin, glucose, uric acid, urea nitrogen, cholesterol, SGOT (soluble glutamic oxaloacetic transaminase) and LDH (lactate dehydrogenase) were surveyed in this study. Generally, the intra-individual differences were too close to the population variances to make this "biochemical profile" of much individualizing value. He noted, however, that better analytical methods might improve the prospects for the use of this kind of profiling in forensic serology.

#### 50.2.3 Hepatitis antigens

One of the best reviews of hepatitis serology may be found in the Nobel address by Blumberg (1977). The discovery of a detectable antigen associated with hepatitis B grew out of studies on the Ag lipoprotein polymorphism (section 45.1). A precipitating antiserum was discovered in the serum of a multiply transfused hemophiliac patient in New York which reacted differently from the known anti-Ag serums. Tested against a panel of sera, the antibody reacted with the serum of an Australian aborigine, and the antigen was given the name "Australia antigen", or "Au". The antigen was found to be very stable in stored sera, and was consistently positive or negative in the same person's serum collected in some cases over a number of successive years. It was noticed that all Au(+) sera came from transfused individuals, and by the end of 1966 it had been realized that Au was associated with acute viral hepatitis. Au could be transmitted by transfusion, and some of the people who received it in this way developed hepatitis. Some such people also developed anti-Au. This finding led to the mass screening of donor blood units for Au prior to any transfusions, and rejection of the Au(+) bloods. The virus responsible for hepatitis B is now known to contain the Australia antigen on its surface, and it is now termed hepatitis B surface antigen (HBsAg). The surface antigen can be removed to reveal a core antigen (HBcAg), and antibodies to both of these can be found in human sera. It turns out that HBsAg exhibits antigenic heterogeneity and a number of surface antigenic determinants (designated by various lower case letters) are known to be associated with the virus. Dmochowski (1976) has given a thorough and readable review of the entire subject of hepatitis, including information about the surface and core antigens and their serology. HBsAg may be detected by a variety of immunological techniques, immunodiffusion, crossed electrophoresis and complement fixation among them. Hemagglutination techniques, in which red cells or latex particles are

coated with anti-HBsAg and used as the test system, have also been described (see, for example, Archer, 1977).

HBsAg can be detected in dried blood. Hoste *et al.* (1977) described a series of studies on a number of experimentally prepared bloodstains using a "sandwich" RIA procedure for detection. HBsAg could be detected in stains up to 6 months old, though more material was needed for testing with the older stains. The presence of HBsAg is a fairly stable characteristic, and can persist for years in people who have it. The incidence of the antigen is fairly low in Western Europe and in this country, but much higher in some populations. HBsAg is sometimes found in so-called carriers, who appear to be healthy. Hoste *et al.* (1977) suggested that HBsAg could provide a useful nongenetic marker in bloodstains. Frazadegan *et al.* (1978) have described detection of HBsAg in blood dried on filter paper, although their interest was not in bloodstain testing *per se*. If HBsAg subtyping should become possible in bloodstains, an even greater discrimination among individuals will probably be possible. Richer *et al.* (1977) have shown, for example, that the frequency of the "e" antigen associated with HBsAg varies among different ethnic groups in the Montreal population.

### 50.3 Serum Protein Profiling

A number of workers have looked at serum protein profiles in different individuals using a variety of different techniques of separation and detection. The number of components resolved is dependent on the nature and resolving capability of the technique selected. In addition, some of the studies were carried out before the extent of serum protein polymorphisms was fully recognized (Unit VII). In any case, if the proteins being profiled are not identified, one can not be sure that one is not seeing an example of a known polymorphic serum protein when a difference is detected.

In 1953, Bernfeld *et al.* found differences in the serum protein profiles of a number of different individuals using moving boundary electrophoresis in a Tiselius cell (section 2.3.1). Brown and Kirk (1957) conducted similar experiments on dried blood using paper electrophoresis. They could distinguish some but not all the stains in a series prepared from ten different people. Laudel *et al.* (1963) could detect differences in the immunoelectrophoretic patterns in the sera of a small number of people after carrying out electrophoresis on cellulose acetate membranes and detecting the proteins with a horse immune anti-human serum.

Whitehead (1969) and Whitehead *et al.* (1970) explored the possibility of using antigen-antibody crossed electrophoresis (Laurell technique—see in section 2.4.3.2) as a means of finding individual differences in the serum protein patterns. Studies with bloodstain extracts indicated that in-

dividual differences could sometimes be seen. The technique was found to be especially valuable for distinguishing Hp phenotype (see in section 40), and the possibility of using the profiling technique to distinguish phenotypes in a number of different immunologically detectable polymorphic serum protein systems simultaneously was discussed. Phillips (1974) looked at a somewhat different approach to serum protein profiling. The quantity of various serum proteins in the sera of different individuals is known to vary. It was thought that these differences might be exploited as individualizing markers using specific antisera and immunochemical quantitation. Antigen-antibody crossed electrophoresis was considered too variable for this purpose, and a nephelometric quantitation procedure using an autoanalyzer was explored. The procedure was found to be unsatisfactory for bloodstain extracts and even to a great extent for older hemolyzed blood samples because of interference by hemoglobin. If suitable techniques could be devised for ridding the samples of hemoglobin, Phillips said, the technique might be very useful, and he recommended further study. Grunbaum and Hjalmarsson (1976) carried out preliminary experiments on aqueous extracts of bloodstains using isotachopheresis (section 2.5.2). There were differences in the patterns from four people, and these patterns did not change if the extracts were retested 24 hours later.

In 1976, Sweet and Elvins (1976a and 1976b) applied antigen-antibody crossed electrophoresis (which they call "crossed electroimmunodiffusion" or CEID—see in section 2.4.3.2) to the problem of distinguishing individual serum protein pattern differences. By selecting and scoring those peaks which showed completely different height ranges over several determinations among individuals being compared, it was possible to distinguish among ten persons in the study. There were five males and five females in the test group, and differences between males and females were noted in the patterns as well. There were a few serum proteins which showed significant differences in amount between the sexes, and it was suggested that analysis of these might provide a probable sex of origin estimate in bloodstains. Whitehead (1977), in a letter prompted by the work of Sweet and Elvins (1976a), pointed out some of the problems associated with serum protein profiling as a means of individualizing stains. He thought that considerably more work would be needed before profiling techniques would be suitable for use in actual casework, and that genetic markers would continue to provide the principal means of individualization available for some time. Sweet (1977) responded to Whitehead's comments in the same issue of *Science*, and did not, for the most part, disagree with them.



## REFERENCES FOR UNIT VIII

- Ando, K. 1973. Studies on the sex identification with human saliva and saliva stains by the analysis of exfoliated oral epithelial cells. *Jpn. J. Leg. Med.* 27: 356-367 §1
- Aragones, J. and J. Egozcue. 1973. A method for sexing 90-day-old bloodstains in absorbent and nonabsorbent material. *Acta Genet. Med. Gemellol.* 22: 113-116
- Archer, A.C. 1977. An improved haemagglutination technique for the detection of hepatitis B<sub>s</sub> antigen. *Med. Lab. Sci.* 34: 345-350
- Barr, M.L. 1957. Cytologic tests of chromosomal sex. *Progr. Gynecol.* 3: 131-141
- Barr, M.L. 1960. Sexual dimorphism in interphase nuclei. *Am. J. Hum. Genet.* 12: 118-127
- Barr, M.L. and E.G. Bertram. 1949. A morphologic distinction between neurones of the male and female, and the behaviour of the nucleolar satellite during accelerated nucleoprotein synthesis. *Nature* 163: 676-677
- Bassett, W.A.G. 1978. Sex determination by sex chromatin identification in the hair root sheath. *J. Canad. Soc. Forensic Sci.* 11: 221-228
- Berghaus, G., U. Reifenberg and G. Dotzauer. 1973. Geschlechtsbestimmung an Skeletteilen. Nachweis der sogenannten Y-Fluoreszenzkörperchen. *Z. Rechtsmed.* 72: 255-268
- Bernfeld, P., V.M. Donahue and F. Homburger. 1953. Characteristic individual electrophoretic patterns in humans. *Proc. Soc. Exp. Biol. Med.* 83: 429-434
- Blažek, J. and J. Bráza. 1972a. Determination of cellular sex in older blood spots and in hair follicle cells with the aid of acridine fluorochromes. *Soudni Lek.* 17: 17-22 [incorporated in *Česk. Patol.* 8 (1972)]
- Blažek, J. and J. Bráza. 1972b. Demonstration of Y-chromosome in necroptic material by fluorescent methods. *Česk. Patol.* 8: 45-49
- Blažek, J. and J. Bráza. 1972c. The method of sex determination in necropsies with the aid of 1-[(6-chloro-2-methoxy-9-acridinyl) amino]-3-(dimethylamino)-2-propanol dihydrochloride. *Česk. Patol.* 8: 108-110
- Blumberg, B.S. 1977. Australia antigen and the biology of hepatitis B. *Science* 197: 17-25
- Brinkmann, B. and U. Jobst. 1973. Bestimmung des Kerngeschlechts an biologischen Supren. Forensischer Beweiswert und Anwendungsbereich. *Z. Rechtsmed.* 73: 1-6
- Brown, C.L. and P.L. Kirk. 1957. Individuality of blood. Electrochromatophoretic patterns of dry blood. *J. Forensic Med.* 4: 58-64
- Caroff, J. and J. Breton. 1966. Le sexe chromatinien—intérêt médico-légal revue générale. *Ann. Med. Leg.* 46: 98-105
- Caspersson, T., S. Farber, G.E. Foley, J. Kudynowski, E.J. Modest, E. Simonsson, U. Wagh and L. Zech. 1968. Chemical differentiation along metaphase chromosomes. *Exp. Cell Res.* 49: 219-222
- Culbertson, J.C., N.A. Breslau, M.K. Moore and E. Eneel. 1969. Sex chromatin determination from hair. *J. Am. Med. Assoc.* 207: 560-561
- Curran, W.J. 1976. Forensic medical science: the continued problems of judges and juries. *New Engl. J. Med.* 294: 1042-1043
- Davidson, W.M. 1963. Leucocytes in blood stains, in: *Forensic Immunology, Medicine, Pathology and Toxicology*, Rept. of 3rd Intl. Meeting, Int. Congr. Ser. No. 80, Excerpta Medica Foundation, Amsterdam & New York
- Davidson, W.M. and D.R. Smith. 1954. A morphological sex difference in the polymorphonuclear neutrophil leucocytes. *Br. Med. J.* 2: 6-7
- De Bernardi, A. 1959. Diagnosi istomorfologica di sesso su sangue imbrattate capelli. *Minerva Medicoleg.* 79: 76-79
- Dixon, A.D. and J.B.D. Torr. 1956. Sex chromatin as an acid to the identification of sex in forensic medicine. *Nature* 178: 797
- Dixon, A.D. and J.B.D. Torr. 1957. Sex determination of human tissues from cell morphology. *J. Forensic Med.* 4: 11-17
- Dmochowski, L. 1976. Viral type A and type B hepatitis. *Am. J. Clin. Pathol.* 65 (suppl. to No. 5): 741-786
- Edwards, J.H. and A.H. Cameron. 1964. Postmortem nuclear sexing. *Lancet* 1: 328
- Farzadegan, H., K.H. Noori and F. Ala. 1978. Detection of hepatitis-B surface antigen in blood and blood products dried on filter paper. *Lancet* 1: 362-363
- George, K.P. 1970. Cytochemical differentiation along human chromosomes. *Nature* 226: 80-81
- Grob, H.S. 1970. Cytologic sexing, in: T.D. Steward (ed.), *Personal Identification in Mass Disasters*, Smithsonian Institution, Washington, D.C.
- Grob, H.S. and H.S. Kupperman. 1961. Experiences with technics of chromatin sex determination. *Am. J. Clin. Pathol.* 36: 132-138
- Grunbaum, B.W. and S.G. Hjalmarsson. 1976. Isotachophoresis of bloodstains. *J. Forensic Sci. Soc.* 16: 325-331
- Holzer, F.J. and E. Marberger. 1957. Zur mikroskopischen Geschlechtsbestimmung an Leichenteilen. *Dtsch. Z. Gesamte Gerichtl. Med.* 46: 242-249
- Hoste, B., J. Brocteur, B. Donea and A. Andre. 1977. Identification of blood stains by non-genetic characteristics: the HBs antigen of viral hepatitis B. *Forensic Sci.* 10: 229-234
- Illig, R. and C. Radriguez de Vera Roda. 1976. Radioimmunologischer Nachweis von TSH in getrockneten Blutstropfen: mögliche Screening-Methode zur Entdeckung der Hyperthyreose bei Neugeborenen. *Schweiz. Med. Wochenschr.* 106: 1676-1681
- Ishizu, H. 1972. Sex identification of hairs by Y-chromosome. *Jpn. J. Leg. Med.* 26: 403-406 §1
- Ishizu, H. 1973. Studies on sex identification of human blood and bloodstains. *Jpn. J. Leg. Med.* 27: 168-181 §1
- Ishizu, H., K. Ando, M. Nobuhara and Y. Mikami. 1973. Sex identification with a minimal sample by combining Y-chromatin identification and the X-chromatin detection method. *Jpn. J. Leg. Med.* 27: 287-294 §1
- Joshi, U.M., H.P. Shah and S.P. Sudhama. 1979. A sensitive and specific enzymeimmunoassay for serum testosterone. *Steroids* 34: 35-46
- King, L.A. 1974a. The identification of anti-parasitic antibodies in bloodstains using an indirect fluorescent antibody technique. *J. Forensic Sci. Soc.* 14: 117-121
- King, L.A. 1974b. The value of biochemical profiling for the discrimination of bloodstains. *J. Forensic Sci. Soc.* 14: 323-327
- King, L.A., D.J. Werrett and P.H. Whitehead. 1975. Antibody profiling of bloodstains. *Forensic Sci.* 5: 144
- King, L.A., D.J. Werrett and P.H. Whitehead. 1976. Antibody profiling of bloodstains. *Forensic Sci.* 8: 151-154
- King, L.A. and P.H. Whitehead. 1975. The differentiation of an adult's bloodstain from that of a child using an indirect fluorescent antibody technique. *Forensic Sci.* 6: 197-203
- Kirk, P.L. and C. Bennett. 1939. A rapid technique for syphilis testing with finger blood. *J. Lab. Clin. Med.* 25: 86-88
- Kovács, M., L. Harsányi and M. Sellyei. 1972. Y-body in cell nuclei of parenchymatous organs. *Z. Rechtsmed.* 71: 104-107
- Kringsholm, B., J.L. Thomsen and K. Henningsen. 1977. Fluorescent Y-chromosomes in hairs and blood stains. *Forensic Sci.* 9: 117-126
- Kringsholm, B., J.L. Thomsen, K.T. Henningsen and E. Niebuhr. 1976. Fluorescent Y-bodies in interphase nuclei: medicolegal aspects of false negative males. *Forensic Sci.* 7: 171-172
- Laudel, A.F., B.W. Grunbaum and P.L. Kirk. 1963. Individuality of human whole dry blood by immunoelectrophoresis on cellulose acetate. *J. Forensic Med.* 10: 57-64
- Leister, C.I. and P.L. Kirk. 1963. Rheumatoid arthritis factor. A sensitive

- method for its detection for individualizing dry blood samples. *J. Forensic Med.* 10: 157-161
- Leister, C.I., J.I. Thornton and P.L. Kirk. 1964. Individualization of dry blood samples. Demonstration of syphilis antibody. *J. Forensic Med.* 11: 31-35
- Montanari, G.D., B. Viterbo and G.R. Montanari. 1967. Sex determination of human hair. *Med. Sci. Law* 7: 208-210
- Moore, K.L. 1966a. Introduction, in: K.L. Moore (ed.), *The Sex Chromatin*, 1-6, W.B. Saunders, Philadelphia & London
- Moore, K.L. 1966b. The discovery of the sex chromatin, in: K.L. Moore (ed.) *The Sex Chromatin*, 7-15, W.B. Saunders, Philadelphia & London
- Moore, K.L. 1966c. Sex chromatin and medicolegal problems, in: K.L. Moore (ed.) *The Sex Chromatin*, 453-464, W.B. Saunders, Philadelphia & London
- Mortimer, C.E., F.P. Smith, L. Errichetto and R.C. Shaler. 1978a. Detection of drugs in a bloodstain. II. Morphine. Paper delivered at 30th Ann. Meeting, Am. Acad. Forensic Sci., St. Louis, MO
- Mortimer, C.E., F.P. Smith and R.C. Shaler. 1978b. Detection of drugs in a bloodstain. III. Digoxin. Paper delivered at 30th Ann. Meeting, Am. Acad. Forensic Sci., St. Louis, MO
- Müller, H., E.M. Bühler, M.G. Voegelin and G.R. Stalder. 1971. Eine neue Methode der Geschlechtsbestimmung in Leukozyten aus eingetrockneten Blutflecken. *Schweiz. Med. Wochenschr.* 101 (32): 1171-1174
- Nagamori, H. 1978. Sex determination from plucked human hairs without epithelial root sheath. *Forensic Sci. Int.* 12: 167-173
- Nanko, S. 1980. Decrease of Y chromatin frequency with time after fixation of blood smear. *Forensic Sci. Int.* 15: 1-2
- Ohno, S. 1966. Single-X derivation of sex chromatin, in: K.L. Moore (ed.) *The Sex Chromatin*, 113-128, W.B. Saunders, Philadelphia & London
- Pearson, P.L., M. Bobrow and C.G. Vosa. 1970. Technique for identifying Y chromosomes in human interphase nuclei. *Nature* 226: 78-80
- Phillips, A.P. 1974. The potential of nephelometric immunoprecipitation quantitation in forensic science. *J. Forensic Sci. Soc.* 14: 135-136
- Phillips, A.P. and E. Gaten. 1971. Y chromosome fluorescence in bloodstains. *Lancet* 2: 371-372
- Phillips, A.P. and C. Gitsam. 1974. The identification of male bloodstains by Y chromosome fluorescence. *J. Forensic Sci. Soc.* 14: 47-54
- Phillips, A.P. and D.F. Webster. 1972. Improved Y-chromosome fluorescence in the presence of magnesium ions. *J. Forensic Sci. Soc.* 12: 361-362
- Radam, G. 1965. Zum Nachweis von Speichelspuren. *Beitr. Gerichtl. Med.* 23: 226-235
- Renard, S. 1971. Determination of sex of exfoliated epithelial cells and its significance in forensic science. *J. Forensic Sci. Soc.* 11: 15-20
- Richer, G., D. Phaneuf, F. Boisvert, R. Guévin and A. Viallet. 1977. Difference in the distribution of e antigen among different ethnic groups in a population of blood donors. *J. Canad. Med. Assoc.* 116: 757-759
- Sakai, K. 1972. Investigation of fluorescent body in the human cells. *Jpn. J. Urol.* 63: 658-671 §<sup>2</sup>
- Sanderson, A.R. and J.S.S. Steward. 1961. Nuclear sexing with acetoorcein. *Br. Med. J.* 2: 1065-1067
- Schaidt, G. and R. Krüger. 1973. Die Geschlechtsbestimmung an Blutproben und Blutspuren männlicher Personen. *Arch. Kriminol.* 151: 41-48
- Schilling, H. 1960. Zur Frage der Dauer der Nachweisbarkeit des Geschlechts an eingesandtem Blut, insbesondere an Blut von Leichen, Dissertation, Berlin (Humboldt), cited by O. Prokop, *Forensische Medizin*, Berlin, 1966
- Schmid, W. 1967. Sex chromatin in hair roots. *Cytogenetics* 6: 342-349
- Schwinger, E. 1972. Geschlechtsbestimmung aus Blutspuren. *Z. Rechtsmed.* 70: 157-162
- Schwinger, E. and H.D. Tröger. 1977. Wie sicher ist die Geschlechtsbestimmung in Blutspuren? *Beitr. Gerichtl. Med.* 35: 267-271
- Shaler, R.C. 1975. The individualization of forensically important physiological fluids, Final Report, Grant #75-NI-99-0011, Nat. Inst. Law Enforcement Crim. Just., Law Enforcement Assistance Administration, U.S. Dept. of Justice, Washington, D.C.
- Sheldon, P.E. and C.J. Coppenger. 1977. A rapid radioimmunoassay for serum testosterone. *Steroids* 30: 149-157
- Smith, F.P. 1980. Detection of drugs in dried bloodstains. IV. Barbiturates. Paper delivered at 32nd Ann. Meeting, Am. Acad. Forensic Sci., New Orleans, LA
- Smith, F.P., R.C. Shaler, C.E. Mortimer and L.E. Errichetto. 1980. Detection of drugs in bloodstains. II. Morphine. *J. Forensic Sci.* 25: 369-373
- Sommermater, J. 1975. Contribution to nuclear sex determination by identification of the Y chromosome in human pulpal fibrocytes. *Forensic Sci.* 5: 167
- Sweet, G.H. 1977. Crossed electroimmunodiffusion and bloodstain investigations. *Science* 198: 427
- Sweet, G.H. and J.W. Elvins. 1976a. Human bloodstains: individualization by crossed electroimmunodiffusion. *Science* 192: 1012-1014
- Sweet, G.H. and J.W. Elvins. 1976b. Studies by crossed electroimmunodiffusion on the individuality and sexual origin of bloodstains. *J. Forensic Sci.* 21: 498-509
- Szendrőnyi, J. and V. Földes. 1980. Messung des Testosterongehaltes in Blutflecken zur kriminalistischen Geschlechtsbestimmung. *Z. Rechtsmed.* 85: 263-267
- Thomsen, J.L. 1975. Eine verbesserte Methode zum Nachweis des Y-Chromosoms in Blutspuren. *Z. Rechtsmed.* 76: 81-86
- Thomsen, J.L. 1978. Influence of the temperature on the detection of fluorescent Y-bodies in blood stains. *Forensic Sci.* 11: 123-126
- Thomsen, J.L. 1979. Y-chromosome detection in bloodstains. *Forensic Sci. Int.* 14: 104
- Thornton, J.I. and P.L. Kirk. 1963. Individualizing dry blood samples by demonstration of the Rhesus antibody. *J. Forensic Med.* 10: 123-127
- Tröger, H.D. and W. Eisenmenger. 1977. Eine Methode zum Nachweis von Scheidenepithelzellen. *Beitr. Gerichtl. Med.* 35: 109-111
- Tröger, H.D. and E. Liebhart. 1974. Zur zeitlichen Nachweisgrenze des Y-Chromosoms an Blutspuren und Haaren. *Beitr. Gerichtl. Med.* 32: 159-162
- Tröger, H.D., E. Liebhart and W. Eisenmenger. 1976. Wer hat die Zigarette geraucht? Bestimmung des männlichen Kerngeschlechts an Mundschleimhautzellen. *Beitr. Gerichtl. Med.* 34: 207-209
- Werrett, D.J., L.A. King and P.H. Whitehead. 1976. The detection of allergen-associated antibodies in bloodstains. *J. Forensic Sci. Soc.* 16: 121-126
- Whitehead, P.H. 1969. Antigen-antibody crossed electrophoresis. A new means of characterizing blood? Proc. 5th Int. Meeting Forensic Sci., Toronto, in: *Int. Microfilm J. Leg. Med.* 4(4): card 10
- Whitehead, P.H. 1977. Crossed electroimmunodiffusion and bloodstain investigations. *Science* 198: 427
- Whitehead, P.H., S.S. Kind, P.A. Morris, M. Davies and R. Cleevley. 1970. The examination of bloodstains by Laurell electrophoresis (antigen/antibody crossed electrophoresis). *J. Forensic Sci. Soc.* 10: 83-90
- Wigmore, R., P. Dolton and P.H. Whitehead. 1979b. The sexing of bloodstains using Y-chromosome fluorescence. Report of a "blind trial" involving 195 casework bloodstains. Tech. Note No. 113, Home Off. Central Res. Establ., Aldermaston, Reading, Berks., England
- Wigmore, R., D.J. Werrett, L.A. King, P.H. Whitehead and A. Emes. 1979a. The detection of Y chromosomes in bloodstains—a reevaluation. *J. Forensic Sci.* 24: 366-375
- Zech, L. 1969. Investigation of metaphase chromosomes with DNA-binding fluorochromes. *Exp. Cell Res.* 58: 463

## Bibliographic Notes to References for Unit VIII

- §<sup>1</sup> *Japanese Journal of Legal Medicine (Jpn. J. Leg. Med.)* has Japanese title *Nippon Hoigaku Zasshi*
- §<sup>2</sup> *Japanese Journal of Urology (Jpn. J. Urol)* has Japanese title *Nippon Hinyokika Gakkai Zasshi*

## INDEX

**ABH Secretor system** (*see* Secretor system)**ABO system:**

- A subgroups: A<sub>1</sub> and A<sub>2</sub>, 266-268
  - anti-A<sub>1</sub> in A<sub>2</sub> and A<sub>2</sub>B sera, 267
  - determination in bloodstains, 312-313
  - quantitation of reactivity, 269-270
  - subgroup A<sub>1</sub>, 268
  - subgroups weaker than A<sub>1</sub>, 268-269
- ABH antigens as widely distributed cell surface structures, 279-280
- acquired B, 279-280
- animal blood ABH receptors, 280
- anti-type XIV pneumococcal serum reactive antigen, 288
- antibodies: anti-H and "anti-O", 272-273
  - anti-A and anti-B, 270-272
  - anti-A from snails, 283
  - anti-H lectins, 273
  - in body fluids other than serum, 273-274
  - cross-reacting anti-A- and anti-B-like antibodies in O sera, 276-278
  - genetic control of, 271
  - origin of "naturally occurring" antibodies, 270-271
  - persistence in dried serum, 300
- antigenic structures, 289
- application to disputed parentage testing, 296-297
- B subgroups or variants, 270, 271
- bacterial ABH receptors, 279-280
- biochemical genetics, 290-293
- blood group enzymes, 287-288, (table) 291
- bloodstain grouping: early studies, 297
  - Landsteiner-Richter test, 297
- bloodstain grouping by elution: of ammoniacal extracts of bloodstains, 307
  - antisera evaluation and selection, 308-310
  - detectability of antigens in aging samples, 310
  - development of technique, 305-306
  - enhancement of blood group antibody reactivity, 309-310
  - interference by adventitious substances and false results, 308
  - sensitivity, 307-308
  - technical development and modifications, 306-307
  - thread technique (Howard-Martin), 307
- bloodstain grouping by ferritin-labelled antibodies, 312
- bloodstain grouping by fluorescent-labelled antibodies, 312
- bloodstain grouping by inhibition: "all or none" technique, 301
  - anti-H reagents and lectins, 304-305
  - detectability of antigens in aging samples, 300-301
  - development of technique, 300-301
  - gamma-globulin deviation, 305
  - Hirszfeld and Amzel-Kind technique, 302-303
  - Holzer technique, 301, 303
  - interpretation of results, 302
  - nonspecific absorption and contamination, 302-304
  - sensitivity, 301
  - use of O (anti-A,B) sera, 300, 301-302
- bloodstain grouping by isoagglutinin detection (Lattes): development of methods, 298-299
  - early work, 298
  - irregular anti-A, and non-ABO antibodies, 299
  - sensitivity and enhancement, 299
  - stability and persistence of isoagglutinins, 299-300

- bloodstain grouping by mixed agglutination: development of technique, 310-312
  - sensitivity, 312
- bloodstain grouping of A antigen by inhibition of hemolysis, 305
- bloodstain grouping using formalin treated red cells, 312
- body fluid and tissue grouping: acquired B in forensic serology, 316-317
  - development, 313
  - of earwax, 316
  - by elution technique, 314-315
  - by fluorescent-labelled antibody technique, 315
  - of gastric mucosa, 316
  - of hair, 320-321
  - heat stability of ABH antigens in teeth, 320
  - by inhibition technique, 313-314
  - of inner ear fluid, 316
  - by mixed agglutination technique, 314
  - of nails, 321-322
  - problems and false reactions, 317-319
  - by reagglutination inhibition technique, 315
  - of skin fragments and organ cells, 316
  - of sweat, 316
  - of teeth, 322
  - of tooth tissues, 316
  - of urine and urine stains, 316
  - (*See also* Secretor system)
- Bombay phenotype, 275-276
- carbohydrate chain-peptide linkage, 289
- characterization of ABH antigens, 287
- cis-AB, 276
- destruction of blood group specificities by enzymatic hydrolysis, 287-288
- discovery, 261
- distribution of phenotypes in U.S. populations, 324-327
- dried serum, 300
- early serological studies, 261-264
- enzymatic degradation of ABH substances, 287-288
- factors affecting typing success in stains and post-mortem samples, 320
- group C, 277-278, 279
- hair grouping, 320-321
- inheritance: cis-AB, 276
  - multiple allelic mode, 264-265, (table) 267
- nomenclature according to Wiener, 277
- nomenclature standardization, 261-262
- numbers of antigenic sites on red cells, 270
- para-Bombay phenotypes, 276
- physicochemical studies of antigen-antibody reaction, 274-275
- plant ABH receptors, 279
- plant, animal and bacterial ABH-like antigens: structural studies, 289
- purification of ABH antigens, 286-289
- quantitative studies of agglutination, 269-270
- quantitative studies of antigen-antibody reaction, 274-275
- relationship of ABO, Secretor and Lewis genotypes to red cell and body fluid antigens, 295
- relationship to *li* antigens, 389
- relationship to Secretor and Lewis, 290-293
- secretion of ABH in body fluids (*see* Secretor system)
- soluble ABH substances (*see* Secretor system)
- subgroups: quantitative designations, 275
- (*See also* A subgroups, B subgroups)

terminal carbohydrates involved in antigenic determinant, 287  
 type 1 and type 2 carbohydrate chain endings, 289  
 type 1 chain conversions to group substances, 293  
 type 2 chain conversions to group substances, 294  
 weak receptor types and unusual antibodies in serum of casework samples, 320

Wiener's conception of, 277-278, 279

#### Absorption-elution:

for ABO grouping of bloodstains (see ABO system, bloodstain grouping by elution)  
 of "cold" agglutinins in bloodstains, 389  
 methods of eluting blood group antibodies from red cells, 310  
 principles involved in evaluation of antisera for, 308-310  
 systematic studies on elution of blood group antibodies from bloodstains, 309-310

(See also Rh system, MNSs system, Kell system, Duffy system, Kidd system)

#### Absorption-inhibition:

for ABO grouping of bloodstains (see ABO system, bloodstain grouping by inhibition)

(See also Inhibition tests, Rh system, MNSs system, Kell system, Duffy system)

**Acetylcholine hydrolase** (see Cholinesterases)

**Acetylcholinesterases** (see Cholinesterases)

**N-acetylgalactosamine:**

involvement in ABH antigen structure, 287  
 structure of, 287

**AChe** (see Cholinesterases)

**ACHy** (see Antichymotrypsin)

**$\alpha_1$ -Acid glycoprotein:**

in seminal plasma, 180, 618  
 serum genetic variants, 617-618

#### Acid phosphatase:

**ACP** locus designations, 447-448  
 assay techniques, 162-163  
 biochemical properties of different isoenzymes, 448-449  
 dye-coupling assay with naphthyl phosphates, 157  
 erythrocyte: application to disputed parentage, 450  
     biochemical properties of isoenzymes, 449-450  
     detectability of isoenzymes in aging blood and bloodstains, 451-452, 453  
     distributions of phenotypes in U.S. populations, 454-455  
     effect of buffers on electrophoretic patterns, 446  
     electrophoretic patterns of phenotypes, 447  
     goodness-of-fit tests on population data, 446  
     grouping in bloodstains, 450-452  
     inheritance and alleles, 445-446  
     phenotyping methods, 452-453  
     phosphotransferase activity of, 451  
     polymorphism, 445  
     recognition of, 445  
     silent alleles, 445-446  
     species determination by isoenzyme separation, 244  
     typing simultaneously with other isoenzyme systems, 452-453  
 linkage relationships of **ACP** loci, 449  
 multiple loci determining, 446-448  
 persistence of seminal enzyme in vagina (see Identification of semen, acid phosphatase)  
 properties of enzyme in human tissues, 446-447  
 prostatic (see Identification of semen, acid phosphatase)  
 red cell (see Acid phosphatase, erythrocyte)  
 salivary polymorphism (see Saliva, polymorphic isoenzymes)  
 seminal: apparent polymorphism, 167-168  
     immunogenicity, 168  
     molecular heterogeneity, 167-168  
     purification and properties, 166-168  
     tartrate inhibition of, 165-166  
 (See also Identification of semen, acid phosphatase)

separation of SAP and VAP, 166

serum level elevated in prostatic carcinoma patients, 155

substrates for, 162-163

units of activity, 163, (table) 164

vaginal, 163-166

**ACP** (see Acid phosphatase)

**Acquired B** (see ABO system, acquired B; ABO system, body fluid and tissue grouping)

**c1 Activator**, 595

**Activity stain**, 423

(See also detection, under specific isoenzyme name headings)

**Acylcholine acyl-hydrolase** (see Cholinesterases)

**ADA** (see Adenosine deaminase)

**Addiment** (see Complement)

**Adenosine aminohydrolase** (see Adenosine deaminase)

**Adenosine deaminase:**

alleles and red cell locus, 457  
 application to disputed parentage, 461  
 biochemical properties of red cell isoenzymes, 460-461  
 biochemical properties of tissue enzymes, 458-459  
 detectability of isoenzymes in aging stains, 461  
 detection of isoenzymes in typing media and assay methods, 460, 461  
 development of red cell isoenzymes in fetal blood, 461  
 distributions of phenotypes in U.S. populations, 462  
 electrophoretic patterns of phenotypes, 458  
 grouping in bloodstains, 461  
 grouping in body fluids and tissues, 462  
 human tissue, 458-459  
 linkage and chromosomal localization of **ADA**, 458  
 polymorphism of red cell enzyme, 457  
 recognition of, 457  
 relationship of deficiency to combined immunodeficiency disease, 457-458, 459-460  
 silent alleles, 457-458  
 sulfhydryl effects on red cell isoenzymes, 460  
 typing simultaneously with other isoenzymes, 461

**Adenylate kinase:**

additional **AK** loci, 440  
 application to disputed parentage, 441  
 biochemical properties, 440-441  
 detectability of isoenzymes in aging blood and bloodstains, 442  
 detection reactions in typing media, 439  
 distributions of phenotypes in U.S. populations, 443  
 electrophoretic patterns of phenotypes, 440  
 grouping in bloodstains, 441  
 grouping in body fluids and tissues, 442  
 polymorphism, 439-440  
 recognition of, 439  
 silent alleles, 440  
 species determination by isoenzyme separation, 244  
 typing simultaneously with other isoenzyme systems, 441-442

**Adler's test** (see Catalytic tests, benzidine)

**Ag system** (see Serum lipoproteins)

**Agar:**

gels for electrophoresis (see Electrophoresis)  
 studies on structure, 60

**Age of bloodstains**, determination of, 131-133

**Agglutination:**

effect of red cell concentration, 299  
 enhancement by high molecular weight colloids, 50-51, 352  
 enhancement by proteolytic enzymes, 51, 353  
 of human cells by animal sera, 236  
 mechanism, 49-51  
 passive: covalent linkage of soluble antigens to blood group antibody, 231  
     tanned red cells, 229-231  
     of sensitized particles (see Sensitized particles)  
 temperature dependence, 52

**Agglutinin binding** (see Absorption-inhibition)

**Agglutinins:**

- antibodies as, 49
- avidity, 53

**A<sub>h</sub>** (see ABO system, para-Bombay phenotypes)

**AK** (see Adenylate kinase)

**Alanine aminotransferase** (see Glutamic-pyruvic transaminase)

**Albumin:**

- characteristics, structure, genetic variants, 620-621
- detectability in aging bloodstains (see Age of bloodstains, determination of)

**Alcaptonuria**, 20

**Aldoses** (see Carbohydrates)

**Alexine** (see Complement)

**A-like antigen** (see ABO system, bacterial and plant ABH receptors)

**Alkaline phosphatase:**

- bone, liver and intestinal enzymes, 509
- description, 128-129
- as one of first isoenzymes, 423
- origin of enzymes in plasma, 128-129
- placental: in forensic diagnosis of pregnancy (see Identification of blood, diagnosis of pregnancy from bloodstains)
- genetic variation and polymorphism, 509-510
- placental-like enzyme in cancer patient serum, 510
- salivary (see Identification of saliva)
- of serum, 509
- in serum of cancer patients, 129

**Alleles:**

- codominant, 30
- defined, 28
- dominant, 27-28
- multiple, 32
- recessive, 28

**Allotype**, 601

**AL-M** (see  $\alpha_2$ -Macroglobulin)

**Aloin test** (see Catalytic tests, aloin)

**ALP** (see Alkaline phosphatase, placental)

**$\alpha$ -Acid glycoprotein** (see Acid glycoprotein)

**$\alpha$ -Antitrypsin** (see Antitrypsin)

**$\alpha$ -M** (see Macroglobulin)

**$\alpha_2$ -Macroglobulin**, 595, 617

**Alpha ( $\alpha$ ) ratio** (see Age of bloodstains, determination of)

**Am markers**, 607

**Amboceptor** (see Hemolysins)

**Amidopyrine** (see Catalytic tests, amidopyrine)

**Amino acids:**

- amphoteric behavior of, 11-12, (illus.) 14
- as components of proteins, 11
- generic structure, 11
- structure of naturally occurring, 13

**3-Aminophthalhydrazide** (see Catalytic tests, luminol)

**Ampholines**, 65

**AMY** (see Amylases)

**Amylases:**

- activity of AMY<sub>2</sub> in semen, 511
- assays with dyed starch substrates, 185-187
- biochemical properties of the isoenzymes, 511-512
- concentration in body fluids, 186
- distribution of phenotypes in U.S. populations, 511
- dyed-starch test papers, 187
- electrophoretic patterns of AMY<sub>1</sub> and AMY<sub>2</sub> phenotypes, 511
- enzymatic properties, 187
- genetic variation and polymorphism, 510-511
- linkage relations of the loci and chromosomal localization, 511
- pancreatic: presence in fecal material, 198
- recognition of amylase enzyme, 184
- salivary and pancreatic isoenzymes, 510-511
- units of activity, 186-187

**Amylopectin** (see Starch)

**Amylose** (see Starch)

**Anamnestic immune response** (see Antibodies, formation)

**Anaphylaxis:**

- as case of immediate hypersensitivity, 56
- description of procedure, 234-235
- identification of semen by (see Identification of semen, immunological)
- species determination by, 234-235
- (See also Hypersensitivity)

**Anti-human globulin serum:**

- detection of incomplete antibodies with, 50, 352-353
- development of, 352
- inhibition of, for human species determination, 227-229, 230
- mixed antiglobulin technique for species determination, 231-232
- and tanned red cells for species determination, 231

**Anti-human hemoglobin** (see Identification of blood, anti-human hemoglobin)

(See also Determination of species, immunological)

**Antibodies:**

- ABO (see ABO system)
- anti-parasitic and anti-allergen as nongenetic markers in blood, 669-670
- binding by antigen-antibody complex, 278
- blocking (see Antibodies, incomplete)
- blood group (see under specific blood group system names)
- in body fluids other than serum, 273-274
- cold, 52
- complete, 49-50
- formation, 45
- Gm (see Gm system)
- to human semen components (see Identification of semen, immunological)
- "hyperimmune", 272
- "immune", 271
- immunoglobulin class of blood group, 48
- incomplete, 50, 352
- "natural", 271
- as nongenetic markers in blood, 669-670
- O serum cross-reacting anti-A- and anti-B-like, 276-278
- profiling (see Nongenetic markers)
- profiling of in serum related to age of bloodstain donor, 130
- Ragg, 603
- to saliva components (see Identification of saliva)
- SNagg, 603
- structure, 45-48
- warm, 52

**Antichymotrypsin**, 595

**Antigen:**

- Australia (see Australia antigen)
- autologous, 44
- blood group: development in fetuses and children (see Genetic marker systems, development in fetuses and children)
- nomenclature conventions, 386
- (See also under specific blood group systems)
- conditions for antigenicity, 43-44
- general nature, 43
- heterologous, 44
- heterophile, 44
- homologous, 44
- nature of antigenic determinant, 44-45
- sperm cell (see Identification of semen, composition of semen)

**Antigen-antibody crossed electrophoresis** (see Immunoelectrophoresis, crossed)

**Antigen-antibody reactions:**

- ABO agglutinin-red cell reactions, quantitative methods, 269-270
- equilibrium treatment of, 50-51
- temperature dependence of agglutinin binding to agglutininogen, 305
- as two-stage event, 48-49
- types, 48-49

- zone phenomena, 52  
(See also Agglutination, Precipitation, Complement Fixation)
- Antiserum:**  
origin of the term, 222  
principles involved in evaluation for bloodstain grouping by elution, 408-310
- Antithrombin III, 595**
- $\alpha_1$ -Antitrypsin:**  
application to disputed parentage, 598  
biochemical properties, 597-598  
in body fluids and tissues, 598  
distribution of phenotypes in U.S. populations, 599  
genetic variation and polymorphism, 595-596  
recognition, 595  
relationship of deficiency to pulmonary degenerative disease, 595, 597  
subtypes of Pi M, 596-597  
typing in bloodstains, 598  
variant nomenclature and standardization, 597
- AP (see Acid phosphatase)**
- Arthus reaction, 56**
- L-Aspartate:2-oxoglutarate aminotransferase (see Glutamic-pyruvic transaminase)**
- Aspermia, 155**
- $\alpha_1$ -AT (see  $\alpha_1$ -Antitrypsin)**
- AT III, (see Antithrombin III)**
- Atkinson phenotypes (see Phosphoglucosmutase, PGM; alleles)**
- ATP:AMP phosphotransferase (see Adenylate kinase)**
- Au<sup>a</sup> (see Auberger antigen)**
- Auberger antigen, 390**
- Australia antigen, 611**  
(See also Hepatitis antigens)
- Avidity (see Agglutinins)**
- Azoospermia, 155**
- Barr bodies (see Sex chromatin)**
- B-cells, 45**
- Behring, Emil A. von (see von Behring)**
- Bence-Jones proteins, 604**
- Benzidine (see Catalytic tests, benzidine)**
- Benzylidene dimethylaniline (see Catalytic tests, benzyldine dimethyl-aniline)**
- Bernstein, Felix, 264**
- Bf (see Complement components, properdin factor B)**
- Bg (see  $\beta_2$ -Glycoprotein I)**
- B<sub>h</sub> (see ABO system, para-Bombay phenotypes)**
- Biebrich scarlet (see Stains, histological)**
- Biuret method (see Proteins, assay methods)**
- B-like antigen (see ABO system, bacterial and plant ABH receptors)**
- Blocking antibody (see Antibody, incomplete)**
- Blood, content of genetic marker proteins in (see Genetic marker systems, content of proteins in blood, body fluids and tissues)**
- Blood component profiling (see Nongenetic markers)**
- Blood crystal tests:**  
acetone chlorhematin crystals, 85  
as certain methods of blood identification, 79  
crystallographic measurements and, 79  
early observations on blood crystals, 79  
hematin crystals: as basis for medico-legal test for blood, 80-84  
effects of bloodstain age on, 84  
effects of heating bloodstains on, 84  
general description, 80  
proof value of positive and negative results in medico-legal tests, 84  
solution of Nippe (1912) and Kirk (1953), 84  
variations in methods and preparation of solutions, 80, 84, (table) 83  
variations in procedure, 80, 84  
hemochromogen crystals: early description of preparation of, 85  
as medicolegal test for blood, 86  
preparation with pyridine, 86  
proof value of positive and negative results in medico-legal tests, 86-87  
studies on properties of, 86  
studies on specificity and sensitivity of Takayama's procedure, 86-87  
Takayama's procedure, introduction in Europe, 86  
Takayama's solutions for preparation of, 86  
variations in methods of preparation of, 85-86  
Takayama crystals (see Blood crystals, hemochromogen crystals)  
Teichmann's crystals (see Blood crystal tests, hematin crystals)  
Wagenaar's crystals (see Blood crystal tests, acetone-chlorhematin crystals)
- Blood group C (see ABO system)**
- Blood group system (see under specific system names)**
- Blood group systems, general considerations, 391-392**
- Blood groups, Wiener designation and nomenclature, 277**
- Blood identification (see Identification of blood)**
- Body fluids and tissues:**  
ABO grouping (see ABO system, body fluid and tissue grouping)  
acid phosphatases, 446-447  
adenosine deaminase isoenzymes, 458-460, 462  
adenylate kinase grouping, 442  
carboxylesterase isoenzymes, 472-473  
DIA, isoenzyme types in, 520  
esterase D isoenzymes, 475  
glucose-6-phosphate dehydrogenase activity, 487  
glutamic-pyruvic transaminase activity, 502  
glyoxalase I grouping, 497  
pepsinogen isoenzymes, 517-518  
peptidase A grouping, 508  
phosphoglucosmutase grouping, 433-435  
6-phosphoglucuronate dehydrogenase grouping, 493  
sex of origin of blood and tissues (see Sex of origin)
- Bombay phenotypes (see ABO system)**
- Booster immune response (see Antibodies, formation)**
- Bordet, Jules:**  
Nobel laureate immunologist, 221, 233  
photo, 5
- Brittain, R.P., 73**
- Bu<sup>a</sup> (see Scianna system)**
- CA (see Carbonic anhydrase)**
- Cad (see Sid and Cad)**
- CAP (see Cystine aminopeptidase)**
- Carbohydrates:**  
chemical definition, 7  
structure and nomenclature, 7  
structure of D-aldoses, 8
- Carbonate hydro-lyase (see Carbonic anhydrase)**
- Carbonic anhydrase:**  
application of CA<sub>II</sub> phenotypes to disputed parentage, 482  
biochemical properties of the isoenzymes, 481-482  
CA<sub>I</sub> locus variants, 480-481  
CA<sub>II</sub> locus variants and polymorphism, 481  
distributions of CA<sub>II</sub> phenotypes in U.S. Black populations, 482  
electrophoretic patterns of CA<sub>II</sub> phenotypes, 482  
electrophoretic patterns of red cell isoenzymes, 480  
genetic loci responsible for isoenzymes, 480  
grouping CA<sub>II</sub> phenotypes in bloodstains, 482  
nomenclature of red cell isoenzymes, 480  
phylogenetic implications of red cell isoenzymes, 482  
recognition of, 479  
red cell isoenzymes, 479  
substrate specificity of red cell isoenzymes, 481  
typing of CA<sub>II</sub> phenotypes simultaneously with other isoenzyme systems, 482
- Carboxylesterases:**  
classification and properties, 469, (table) 470  
genetic interpretation of tissue and red cell isoenzymes, 472-473, (table) 474

- human tissue, 472-473
- red cell: application to disputed parentage testing, 473
- biochemical properties of isoenzymes, 471-472
- distribution of esterase D phenotypes in U.S. populations, 476-477
- electrophoretic patterns of, 472
- electrophoretic patterns of esterase D phenotypes, 473
- esterase D polymorphism, 471
- esterase D typing in body fluids and tissues, 475
- genetic variation of A esterases, 471
- isoenzymes of, 469-471
- simultaneous typing of esterase D and other isoenzyme systems, 475
- salivary polymorphic (see Saliva, polymorphic isoenzymes)
- o*-Carboxyphosphate (see Acid phosphatase, substrates)
- Carcinoplacental enzyme antigen (see Regan isoenzyme)
- $\beta$ -Carotene, 12
- Carotenoids (see Lipids)
- Catalase, general reaction, 101
- Catalytic tests:
- aloin: structure of barbaloin, 104
- as test for blood, 103
- amidopyrine, 110-111, (structure) 112
- benzidine: carcinogenicity, 107-108
- certainty of positive test as test for blood, 105-107
- dangers due to carcinogenicity, 108
- introduction as medicolegal blood test, 105
- oxidation and structure of oxidation product, 106
- sensitivity, 107
- specificity, 105-107
- structure, 106
- substances giving false positive results, 105-107
- benzylidine dimethylaniline, 111
- chlorpromazine, 111-112
- 2,7-diaminofluorene, 109
- o*-dianisidine: as basis of medicolegal blood test, 110
- carcinogenicity, 110
- structure, 111
- diphenylamine, 112
- eosin, 109
- evidential (probative) value of positive results, 116
- fluorescein, 112
- general discussion of basis of, 101
- guaiacum: composition of guaiacum blue, 102
- composition of guaiacum resin, 101
- early examples of use in medicolegal cases, 101-102
- early studies on peroxidase activity of blood, 101
- false positives, substances and materials giving, 102
- of historical interest as medicolegal blood test, 103
- interpretation of results with bloodstains, 102
- medicolegal blood identification and, 101-102
- sensitivity, 102-103
- leucocrystal violet: as basis of medicolegal blood test, 108
- structure, 108
- leucomalachite green: as basis of medicolegal blood test, 108
- specificity and sensitivity, 108-109
- structure, 108
- luminol: as basis of medicolegal blood test, 112-114
- chemiluminescence reaction mechanisms, 115, 116
- chemiluminescence reactions, 114
- structure, 113-114
- peroxidase activity of blood, 101
- peroxidase activity of hemoglobin, 101
- peroxidase reaction, generalized, 101
- peroxide, 109
- phenolphthalin: evaluation of, as medicolegal test for blood, 104-105
- oxidation of, as test for "oxidases", 103
- preparation of reagent for blood test, 104
- sensitivity, 103-104
- specificity, 104
- structure and oxidation, 104
- as test for blood, 103
- p*-phenylenediamine, 110
- rhodamine B, 109-110
- specificity and interpretation of results, 114-116
- tetramethylbenzidine: as basis of medicolegal blood test, 111
- structure, 112
- o*-toluidine: as basis of medicolegal blood test, 110
- carcinogenicity of, 110
- structure, 110
- o*-toluidine, 110-111
- Cellobiose, 9
- Cerebroside (see Glycolipids)
- Ceruloplasmin:
- deficiency and Wilson's disease, 619
- recognition, properties and polymorphism, 618-619
- Cervical mucus (see Vaginal secretions)
- Ch<sup>a</sup> (see Complement components, C4)
- Chi-square (see Population genetics)
- Chido (see Complement components, C4)
- Chlorpromazine (see Catalytic tests, chlorpromazine)
- Cholesterol, 11
- Choline, 174
- (See also Identification of semen)
- Cholinesterases:
- of blood, 463
- classes of, 463
- as neurotransmitter, 463
- recognition of, 463
- red cell acetylcholinesterase, 463-464
- serum pseudocholinesterase: alcohol inhibition and alcohol number, 465
- assay procedures and detection of *E*<sub>1</sub> variants, 468-469
- biochemical properties of isoenzymes, 467-468
- chloride inhibition and chloride number, 465
- detection of *E*<sub>1</sub> phenotypes in bloodstains, 473-474
- dibucaine inhibition and dibucaine number, 464-465
- distribution of *E*<sub>1</sub> and *E*<sub>2</sub> locus phenotypes in U.S. populations, 476-477
- electrophoretic variants, 465-466
- fluoride inhibition and fluoride number, 465
- general description, 463
- genetic loci responsible for variants (*E*<sub>1</sub> and *E*<sub>2</sub>), 466
- genetic variation of, 464-467
- nomenclature and properties of variants, 466
- relationship of genetic variation to succinylcholine sensitivity, 464
- screening procedure for *E*<sub>1</sub> variants, 468-469
- silent alleles at *E*<sub>1</sub>, 466-467
- standard assay conditions, 464
- typing of *E*<sub>2</sub> locus electrophoretic variants in bloodstains, 475
- Chromatographic methods:
- for blood identification (see Identification of blood)
- for concentration of diluted blood samples, 119-120
- for identification of semen (see Identification of semen)
- for identification of urine (see Identification of urine)
- for separation of blood from debris, 119-120
- Chromatography:
- gel filtration, 14-15
- as method for estimation of MW of proteins, 16
- ion exchange, 14
- Chromosomes:
- in cell division, 25-26
- diploid number, 26
- genetic map of human, 36-37
- haploid number, 26
- homologous, 26
- sex determination and, 26-27
- Chronic granulomatous disease (CGD), relationship to Kell blood group system, 370-371

- Chronic obstructive pulmonary disease**, relationship to  $\alpha_1$ -antitrypsin deficiency, 595, 597
- CI** (see Stains, histological)
- Cibachron blau F3G-A starch**, 185
- CID** (see Combined immunodeficiency disease)
- Co** (see Colton system)
- "Cold" agglutinins** (see Ii system)
- and bloodstains (see Absorption-elution)
- Colton system**, 390
- Combined immunodeficiency disease**, relationship to ADA deficiency, 457-458, 459-460
- Complement**:
- cascade, 55, (illus.) 56
  - components, 54-55
  - description of, 54-55
  - pathways, 55
  - unit of, 55
- Complement components**:
- C2, 614-615
  - C3, 615
  - C4, 615-616
  - C6, C7 and C8, 616
  - polymorphism of, 614
  - properdin factor B, 617
- Complement fixation**:
- description of, 55, 233
  - immunological species of origin test, 234
- Concentration of dilute blood samples** (see Chromatographic methods)
- c1 Activator**, 595
- c1-ina** (see c1 Activator)
- Coombs serum** (see Anti-human globulin serum)
- Coombs test** (see Anti-human globulin serum, detection of incomplete antibodies with)
- Copper binding protein** (see Ceruloplasmin)
- Cp** (see Ceruloplasmin)
- CPK** (see Creatine phosphokinase)
- Creatine phosphokinase** (see Identification of semen)
- Cross-immunization** (see Determination of species, immunological cross-reactions)
- Cross-reactions of species antisera** (see Determination of species, immunological)
- Crossed electroimmunodiffusion** (see Immunoelectrophoresis, crossed)
- Cryptantigens**, 339
- C2, C3, C4, C6, C7, C8** (see Complement components)
- Cystine aminopeptidase** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Cytochrome b<sub>5</sub> reductase** (see Diaphorases)
- Day's test** (see Catalytic tests, guaiacum)
- Db** (see Saliva, polymorphic protein systems)
- Detectability of genetic markers in aging samples** (see Genetic marker systems, detectability in aging samples)
- Determination of species**:
- chemical methods of historical interest, 215
  - fibrin plate method, 243
  - gamma globulin deviation, 237
  - hemoglobin denaturation with alkali, 243
  - hemoglobin separations for, 244
  - historical, 215-217
  - immunological: adjuvants in antiserum preparation, 224
  - agglutinins in animal sera as basis of, 236
  - agglutination of human cells by animal sera, 236
  - anaphylaxis, 234-235
  - anti-human globulin serum inhibition, 227-229, 230
  - anti-human hemoglobin sera, 227
  - bloodstain washing, effects on precipitin test, 226
  - complement fixation, 233-234
  - cross over immunoelectrophoresis, 225
  - cross-reactions of antisera to related species, 239-241
  - development of precipitin test, 221-224
  - double immunodiffusion as forensic species test, 225
  - double immunodiffusion technique development, 224-225
  - external influences effects on precipitin test, 225-226
  - fluorescent antibody technique, 237-238
  - heating of bloodstains, effect on precipitin test, 226
  - hemolysins, 235-236
  - immunoelectrophoresis, 238
  - mixed antiglobulin technique, 231-232
  - optimization of precipitin reaction conditions, 227
  - origins of precipitin test, 221-222
  - phylogenetic relationship and antibody cross-reactivity, 241
  - phytoprecipitins, 237
  - precipitation-inhibition, 226
  - precipitin test applied to game killing cases, 223
  - precipitin test, early studies, 221-224
  - precipitin test for differentiating meats, 223
  - preparation of precipitating antisera, 223-224
  - protein concentration estimation in bloodstain extracts, 227
  - quantitative precipitation techniques, 238-239
  - ring test, 224
  - sensitized colloidal particles, 231-233
  - sensitized latex particles, 233
  - serum-hemoglobin precipitation, 236-237
  - single immunodiffusion technique development, 224
  - specific antisera against human and animal blood, 222-224
  - substratum effects on precipitin test, 225-226
  - tanned red cell hemagglutination technique, 231
  - tanned red cell technique for discrimination of closely related species, 239
  - turbidimetry, 238-239
  - isozyme separation for, 244
- micrometry**, 215-217
- cases of historical interest, 216-217
  - (See also Red blood cell, measurement)
- odor** (see Determination of species, chemical methods of historical interest)
- tissues**, 244
- Di** (see Diego system)
- 2,7-Diaminofluorene** (see Catalytic tests, 2,7-diaminofluorene)
- o-Dianisidine**:
- as catalytic test reagent (see Catalytic tests)
  - as reagent for detection of Hp-Hb complexes (see Haptoglobin, detection in typing media)
- Dianisidine blue** (see Naphthyl Diazo Blue B)
- Diaphorases**:
- biochemical properties, 519-520
  - description and properties, 518
  - DIA, phenotype distribution in populations, 520
  - multiple genetic loci and polymorphism, 518-519
  - sperm diaphorase, 519
- Diastase** (see Amylase)
- Dibucaine**, 464
- (See also Cholinesterases)
- Diego system**, 389-390
- Dimethyl-p-nitrophenyl phosphate**, 469
- (See also Carboxylesterases)
- Diphenylamine** (see Catalytic tests)
- Discrimination index** (see Population genetics)
- Disputed parentage testing**:
- ABO system, 296-297
  - adenosine deaminase system, 461
  - adenylate kinase system, 441
  - Ag system, 613
  - carbonic anhydrase II system, 482
  - Duffy system, 373
  - early developments in ABO applications, 296
  - erythrocyte acid phosphatase system, 450
  - esterase D system, 473



- galactose-1-phosphate uridylyl transferase variants, 515  
 genetic marker systems and, 257-258  
 glutamic-pyruvic transaminase system, 502  
 glyoxalase I system, 496-497  
 Gm and Km systems, 608  
 group specific component, 584-585  
 haptoglobin system, 577  
 hemoglobin variants, 555  
 HLA system, 629-630  
 Kell system, 371-372  
 Kidd system, 375  
 Lutheran system, 387  
 MNSs system, 342-343  
 P system, 385  
 peptidase A system, 507  
 phosphoglucomutase system, 430  
 6-phosphogluconate dehydrogenase system, 492  
 polymorphic proteins of saliva, 635  
 primary or first order exclusions, 257  
 probability of exclusion, 258  
 Rh system, 361-362  
 secondary or second order exclusions, 257  
 secretor system, 297, 313  
 transferrin system, 593
- DNA:**  
 as the genetic material, 21  
 replication, 23, 28  
 structure, 21-23, 26-27
- Do** (see Dombrock system)
- Döderlein's bacillus** (see Vaginal secretions)
- Dombrock system**, 390
- Drugs**, as nongenetic markers in bloodstains, 670
- Duffy system**, 372-373  
 distribution of phenotypes in U.S. populations, 378-379
- Dye-binding method** (see Proteins, assay methods)
- EAP** (see Acid phosphatase, erythrocyte)
- Earwax**, ABO grouping of (see ABO system, body fluid and tissue grouping)
- E.C. [Enzyme Commission]** (see Enzymes, nomenclature)
- E.C. 1.1.1.27** (see Lactate dehydrogenase)
- E.C. 1.1.1.44** (see 6-Phosphogluconate dehydrogenase)
- E.C. 1.1.1.49** (see Glucose-6-phosphate dehydrogenase)
- E.C. 1.6.2.2** (see Diaphorases)
- E.C. 1.6.4.2** (see Glutathione reductase)
- E.C. 1.11.1.9** (see Glutathione peroxidase)
- E.C. 1.15.1.1** (see Superoxide dismutase)
- E.C. 1.16.3.1** (see Ceruloplasmin)
- E.C. 2.6.1.2** (see Glutamic-pyruvic transaminase)
- E.C. 2.7.1.1** (see Hexokinase)
- E.C. 2.7.3.2** (see Creatine phosphokinase)
- E.C. 2.7.4.3** (see Adenylate kinase)
- E.C. 2.7.5.1** (see Phosphoglucomutase)
- E.C. 2.7.7.12** (see Galactose-1-phosphate uridylyl transferase)
- E.C. 3.1.1.7** (see Cholinesterases)
- E.C. 3.1.1.8** (see Cholinesterases)
- E.C. 3.1.3.1** (see Alkaline phosphatase)
- E.C. 3.1.3.2** (see Acid phosphatase)
- E.C. 3.1.3.18** (see Phosphoglycolate phosphatase)
- E.C. 3.2.1.1** (see Amylases)
- E.C. 3.4.1.1** (see Leucine aminopeptidase)
- E.C. 3.5.4.4** (see Adenosine deaminase)
- E.C. 4.2.1.1** (see Carbonic anhydrase)
- E.C. 4.4.1.5** (see Glyoxalase I)
- E.C. 5.3.1.9** (see Glucose phosphate isomerase)
- Ehrlich, Paul:**  
 Nobel laureate immunologist, 221  
 photo, 5
- Electroimmunodiffusion** (see Immunelectrophoresis)
- Electrophoresis:**  
 agar gel: development of technique, 60  
 electroendosmosis, 60  
 blood identification using (see Identification of blood, electrophoretic methods)  
 cellulose acetate membrane, development of technique, 60-61  
 cross over (see Immunelectrophoresis, cross over)  
 description, 58  
 immunofixation (see Immunofixation electrophoresis)  
 mechanisms, 58-59  
 paper, 59  
 polyacrylamide gel: development of technique, 61-62  
 disc electrophoresis, 61-62  
 flat gel electrophoresis, 62  
 of serum proteins, (illus.) 567  
 starch gel, development of technique, 59-60
- Electrosynthesis** (see Immunelectrophoresis, cross over)
- Elek, S.D.**, 224
- Elution of blood group antibodies from red cells**, 310
- Enzyme Commission** (see Enzymes, nomenclature)
- Enzymes:**  
 cofactors and coenzymes, 19  
 inhibitors, 18-19  
 kinetics of enzyme-catalyzed reactions, 16-19  
 multiple molecular forms of (see Isoenzymes)  
 nomenclature, 16  
 origin of the term, 184  
 (See also under specific enzyme names)
- Eosin:**  
 as catalytic blood test reagent (see Catalytic tests, eosin)  
 as histological stain (see Stains, histological)
- Erythrocyte acid phosphatase** (see Acid phosphatase, erythrocyte)
- ESD** (see Carboxylesterases, red cell)
- E-600** (see Diethyl-p-nitrophenyl phosphate)
- Esterase D** (see Carboxylesterases, red cell)
- Esterases:**  
 categories of, 463  
 as one of first isoenzymes, 423  
 of semen and sperm (see Identification of semen)  
 species determination by isoenzyme separation, 244  
 (See also Carboxylesterases, Cholinesterases, Carbonic Anhydrase)
- Estradiol**, 12, 668
- Exclusions** (see Disputed parentage testing)
- Fatty acids** (see Lipids)
- Fast Blue B** (see Naphthanil Diazo Blue B)
- Fast Garnet B**, 157, 158
- Fast Red AL** (see Naphthanil Diazo Red AL)
- Fast Red RC** (see Naphthanil Diazo Red RC)
- F-bodies:**  
 description, 666  
 as sex of origin indicator in bloodstains, 666-667  
 as sex of origin indicator in tissues, 667-668
- Fecal material** (see Identification of fecal material)
- Ferritin-labelled antibodies for ABO grouping**, 312
- $\alpha_1$ -Fetoprotein** (see Identification of blood, fetal and infant blood diagnosis)
- Feulgen stain** (see Stains, histological)
- Fibrin plate method:**  
 for menstrual blood identification, 123-124  
 for species determination, 243
- Fibrinolytic system**, 122-123, 125  
 (See also Identification of blood, menstrual blood)
- Fluorescence:**  
 saliva stains (see Identification of saliva)  
 seminal stains (see Identification of semen)  
 urine stains (see Identification of urine)
- Fluorescent-labelled antibodies**, for ABO and MN grouping, 312
- Fluorescein** (see Catalytic tests, fluorescein)

- Folin-Ciocalteu reagent**, for protein assay, 15
- Forsman antigen** (see Antigens, heterophile)
- FOUR** (see HLA system)
- Fructose**, as marker for semen identification, 175
- $\alpha$ -L-Fucose**:  
involvement in ABH antigen structure, 287  
structure, 287
- Furanoses** (see Carbohydrates)
- Fy** (see Duffy system)
- Galactokinase**, 514-515  
genetic variants and deficiencies, 515  
relationship of deficiencies to cataracts, 515
- N-acetyl-Galactosamine** (see Acetyl-galactosamine)
- Galactose-1-phosphate uridylyl transferase**:  
application to disputed parentage testing, 515  
biochemical properties, 515  
distribution of phenotypes in U.S. populations, 514-515  
electrophoretic patterns of phenotypes, 514  
genetic variation and galactosemia, 513-514  
recognition and metabolic role, 512-513
- Galactosemia** (see Galactose-1-phosphate uridylyl transferase)
- GALK** (see Galactokinase)
- Gal-1-PUT** (see Galactose-1-phosphate uridylyl transferase)
- GALT** (see Galactose-1-phosphate uridylyl transferase)
- Gangliosides** (see Glycolipids)
- Garrod, Archibald E.**, 20
- Gastric mucosa**, ABO typing (see ABO system, body fluid and tissue grouping)
- GBG** (see Complement components, properdin factor B)
- Gc** (see Group specific component)
- Gd** (see Glucose-6-phosphate dehydrogenase)
- Gel filtration** (see Chromatography)
- Gene frequency**, 39
- Genetic code**, 24-25, 30
- Genetic map of human chromosomes**, 36-37
- Genetic mapping**, 33
- Genetic marker systems**:  
applications in forensic serology, 257-258  
blood and body fluid individualization using, 258  
classes of, 257  
content of proteins in blood, body fluids and tissues: adenosine deaminase, 462  
adenylate kinase, 442  
 $\alpha$ -antitrypsin, 598  
concentration ranges of serum proteins in serum, 563-564  
esterase D, 475  
glucose-6-phosphate dehydrogenase, 487  
glutamic-pyruvic transaminase, 501-502  
 $\beta$ -glycoprotein I, 621  
glyoxalase I, 497  
Gm and Km, 609-610  
group specific component, 584, 585  
haptoglobin, 569, 579  
hemoglobin, 545  
isoenzyme assays in diagnosis of deficiency types, 490, 502  
 $\alpha$ -macroglobulin, 617  
peptidase A, 508  
phosphoglucomutase, 435  
6-phosphogluconate dehydrogenase, 490, 493  
transferrin, 593  
detectability in aging samples: ABO antigens, 300-301, 310  
ABO isoagglutinins, 299-300  
adenosine deaminase isoenzymes, 461  
adenylate kinase isoenzymes, 442  
Duffy antigens, 373  
erythrocyte acid phosphatase isoenzymes, 451-452, 453  
esterase D isoenzymes, 475  
Kell antigens, 372  
Kidd antigens, 375  
MNSs antigens, 344, 345  
phosphoglucomutase isoenzymes, 432-433  
Rh antigens, 362-363  
development in fetuses and children: adenosine deaminase, 461  
adenylate kinase, 441  
Duffy antigens, 373  
glutamic-pyruvic transaminase, 502  
Kidd antigens, 374  
Lewis antigens, 329  
Lutheran antigens, 387  
P antigens, 383  
peptidase isoenzymes, 507  
phosphoglucomutase, 430  
6-phosphogluconate dehydrogenase, 492  
disputed parentage testing and, 257  
table of, 259  
table of discrimination indexes, 259  
table of probabilities of exclusion of paternity, 259
- Genetics**:  
development as a science, 20  
origin of the term, 20  
(See also Inheritance)
- Genotype**, 27
- Giemsa stain** (see Stains, histological)
- G1** (see Saliva, polymorphic protein systems)
- Glc-6PD** (see Glucose-6-phosphate dehydrogenase)
- GLO** (see Glyoxalase I)
- 1,4- $\alpha$ -D-Glucan glucanohydrolase** (see Amylases)
- D-Glucopyranoses**, 9
- $\alpha$ -D-Glucose-1,6-diphosphate: $\alpha$ -D-glucose-1-phosphate phosphotransferase** (see Phosphoglucomutase)
- Glucose-6-phosphate dehydrogenase**:  
biochemical properties of isoenzymes, 486-487  
detection in typing media, 487  
distribution of phenotypes in U.S. populations, 489  
electrophoretic patterns of common phenotypes, 488  
genetic variation in red cell enzyme, 483-484  
grouping in bloodstains, 487  
inactivating effect of red cell stroma, 487  
metabolic role in cell, 484-485  
nomenclature of red cell genetic variants, 484-486  
recognition of, 483  
red cell genetic variants of, 484-486  
relationship of genetic variation of red cell enzyme to induced hemolytic anemia, 483-484  
relationship of X-linkage of *Gd* and Lyon hypothesis, 486  
salivary polymorphic (see Saliva, polymorphic isoenzymes)  
in semen and spermatozoa, 487  
X-linkage of *Gd* locus, 486
- Glucose phosphate isomerase**, 515-516
- D-Glucose-6-phosphate:NADP<sup>+</sup>-1-oxidoreductase** (see Glucose-6-phosphate dehydrogenase)
- Glutamic-alanine transaminase** (see Glutamic-pyruvic transaminase)
- Glutamic-pyruvic transaminase**:  
activity in body fluids and tissues, 502  
apparent quantitative genetic variation, 502  
application to disputed parentage testing, 502  
biochemical properties of isoenzymes, 501-502  
detection reactions in typing media, 501  
distribution of phenotypes in U.S. populations, 502  
electrophoretic patterns of phenotypes, 500  
genetic variation and polymorphism, 499  
grouping in bloodstains, 502  
phenotyping procedures, 500-501  
recognition of, 499  
silent alleles, 499, 502
- Glutathione peroxidase**, 516
- Glutathione reductase**, 516

**Glycerophosphates** (see Acid phosphatase, substrates)

**Glycine-rich- $\beta$ -glycoprotein** (see Complement components, properdin factor B)

**Glycolipids:**

- cerebrosides and gangliosides, 7
- as class of lipids, 7

**3.5S  $\alpha_1$ -Glycoprotein** (see  $\alpha_1$ -Antitrypsin)

**$\beta_2$ -Glycoprotein I**, 621

**$\beta_2$ -Glycoprotein II** (see Complement components, properdin factor B)

**Glyoxalase I:**

- application to disputed parentage testing, 496-497
- assay procedures, 495
- biochemical properties of isoenzymes, 496
- detection reactions in typing media, 495-496, 497
- distributions of phenotypes in U.S. populations, 497-498
- electrophoretic patterns of phenotypes, 496
- genetic variation and polymorphism, 495
- grouping in bloodstains, 497
- grouping in body fluids and tissues, 497
- recognition of, 495
- typing simultaneously with other isoenzyme systems, 497

**Glyoxalase II**, 495

**Gm system:**

- application to disputed parentage testing, 608
- assignment of factors to IgG subclasses, 604
- distribution of phenotypes in U.S. populations, 610
- factors and nomenclature, 601-604, (table) 602
- genes and expression in cells, 604
- genetics and inheritance, 605-606
- nonmarkers, 604-605
- recognition of, as inherited factors, 601
- typing in bloodstains, 608-609
- typing in body fluids and tissues, 609-610
- typing methods, 607-608

**GPI** (see Glucose phosphate isomerase)

**GPT** (see Glutamic-pyruvic transaminase)

**GPX** (see Glutathione peroxidase)

**Group specific component:**

- application to disputed parentage testing, 584-585
- biochemical properties, 584
- distribution of phenotypes in U.S. populations, 586-587
- electrophoretic patterns of phenotypes, 582
- genetic variation and polymorphism, 581-583
- methods of phenotyping, 583-584
- nomenclature of variants, 583
- occurrence in body fluids, 585
- physiological role, 584
- recognition of, 581
- serum concentration of proteins, 584
- subtyping of Gc 1, 583
- typing in bloodstains, 585
- variants, 581-583
- variation in patterns in newborn and infant blood, 130
- as vitamin D binding protein, 584

**Group specific double combination method**, 311

**GSR** (see Glutathione reductase)

**Guaiacum** (see Catalytic tests, guaiacum)

**Hair:**

- ABO grouping of (see ABO system)
- isoenzymes in hair roots, summary, 637
- polymorphic structural proteins of, 637

**Haplotype**, 601

**Haptoglobin:**

- as antibody against streptococcal surface antigen, 569
- application to disputed parentage testing, 577
- biochemical genetics, 575-577
- chloroform extraction procedure for bloodstains, 578-579
- classification of variants, 570

content in serum, 569

detection in typing media: with catalytic blood test reagents for Hp-Hb complex, 578

*o*-dianisidine as reagent for, 110

use of guaiacol for, 103

distribution of phenotypes in U.S. populations, 579-580

electrophoretic patterns of common types and subtypes, 571

electrophoretic patterns of variants, 573

genetic variation and polymorphism, 569-573

occurrence in body fluids, 579

physiological role, 569

recognition of, 569

structural gene duplication, 575-577

structure: of Hp-Hb complex, 574-575

polypeptide chains, 575

subunit, 573-574

subtypes of Hp 1, 570

typing in bloodstains, 577-579

**Hardy-Weinberg equilibrium** (see Population genetics)

**Hb** (see Hemoglobin)

**HbAg** (see Hepatitis antigens)

**HCG** (see Human chorionic gonadotropin)

**He** (see MNSs system, associated antigens)

**Heating**, effects on bloodstain component solubility, 84, 226

**Hemagglutination inhibition** (see Inhibition tests)

**Hematoporphyrin** (see Identification of blood, spectral tests)

**Hematoxylin** (see Stains, histological)

**Heme and hematin compounds:**

- description, 77-79
- interrelationships, 82
- structure and nomenclature, 77-79, 81
- structure of heme, 77, 80

**Hemizygosity**, 34

**Hemoglobin:**

- application of genetic variants to disputed parentage testing, 555
- biochemical genetics, 554
- content in blood, 545
- distribution of phenotypes in U.S. populations, 560-561
- electrophoretic and isoelectric focusing methods of characterization, 554-555, 556-557
- fetal: alkali denaturation characteristics, 129
  - as marker for fetal and infant blood (see Identification of blood, fetal and infant blood diagnosis)
- structure, 547-549
- as genetic marker system, 545
- genetic variants, 549-553
- nomenclature of variants, 553
- origin of the name, 93
- serum precipitation of (see Determination of species, immunological)
- sickle cell, 550
- sickle cell and balanced polymorphism, 558
- species determination by alkali denaturation, 243
- species determination by separation of, 244
- spectral properties, 89-91
- spectral properties as means of blood identification (see Identification of blood, spectral tests)
- structural gene duplication, 554
- structure: embryonic and fetal, 547-549
  - of polypeptide chains, 545-549
  - tetrameric, 545, (figure) 549
  - three-dimensional, 547
- typing of variants in bloodstains, 555, 558
- variants distribution in world populations, 558-559

**Hemoglobin F** (see Hemoglobin, fetal)

**Hemolysins:**

- antibodies as, 49
- in complement fixation reactions, 55
- species determination and, 235-236

**Hepatitis antigens**, 670-671

**Heterozygosity**, 29

**Hexokinase**, 516-517

**Hirszfeld, Ludwig**, 254

**Histocompatibility** (see HLA system)

**HK** (see Hexokinase)

**HLA system**:

A and B locus antigens, 624-625

antigens in semen, 630

application to disputed parentage testing, 629-630

biochemical properties of antigens, 628-629

C locus antigens, 626-627

D and DR locus antigens, 627-628

definition of specificities, 624

genetics, chromosomal localization and linkage relations, 625-626

lymphocyte defined antigens, 627

mixed lymphocyte culture (MLC) test, 627

recognition and general description, 623-624

serologically defined antigens, 624-625

testing and typing procedures, 628

typing in bloodstains, 630

**H-like antigen** (see ABO system, plant and bacterial ABH receptors)

**Holzer, Franz Josef** (see Unit IX)

**Homozygosity**, 29

**Horror autotoxicus**, 43

**Hp** (see Haptoglobin)

**HPL** (see Human placental lactogen)

**H-type precipitating antisera**, 53-54

**Hu** (see MNSs system, associated antigens)

**Human chorionic gonadotropin**, detection by sensitized particle technique, 233

(See also Identification of blood, diagnosis of pregnancy from bloodstains)

**Human placental lactogen** (see Identification of blood, diagnosis of pregnancy from bloodstains)

**Hv markers**, 607

**Hypersensitivity**:

delayed, 56

immediate, 55-56

**IaI** (see Inter- $\alpha$ -trypsin inhibitor)

**Identification of blood**:

age of bloodstain donor correlated with serum antibody profile, 130

anti-human hemoglobin: anti-Hb F for fetal blood identification, 118

antisera to Hb A and Hb F, 117-118

medicolegal tests for identifying dried blood, 117-118

preparation of antiserum, 117

catalytic tests for (see Catalytic tests)

crystal tests (see Blood crystal tests)

diagnosis of pregnancy from bloodstains: cystine aminopeptidase, 128

leucine aminopeptidase, 128

placental alkaline phosphatase, 128-129

pregnancy-associated proteins, 127-128

pregnancy hormones, 126-127

electrophoretic methods, 120

fetal and infant blood diagnosis: fetal hemoglobin, 129

$\alpha_1$ -fetoprotein, 129-130

variations in Gc pattern, 130

heating test, 120

history, ancient and mediaeval, 73

menstrual blood: fibrinolytic properties, 122

glycogen-containing epithelial cells in, 121-122

LDH isoenzyme profile as diagnostic of, 125-126

methods based on fibrinolytic activity, 122-124

microscopical and histological methods for, 121-122

preparation of antisera against, 124

toxicity bioassays for, 124-125

microscopical methods: histological staining of blood cells from bloodstain extracts, 96-97

history and general discussion, 94-96

identification of blood cells, 96-97

isolation and identification of white cells, 96-97

"reconstitution" of red cells from bloodstains, 96

transfer methods for bloodstains, 96-97

origins, 74-75

paper chromatographic methods, 119

spectral tests: effects of environmental influences on bloodstains, 93-94

general considerations, 89

general features of visible spectra of hemoglobin and derivatives, 90-91

hematoporphyrin, different methods of preparation, 94

hematoporphyrin fluorescence as medicolegal test for blood, 94

hematoporphyrin fluorescence properties, 94

historical development, 89-93

transformation of hemoglobin into derivatives and their spectral properties, 90-93

thin-layer chromatographic methods, 119

**Identification of fecal material**:

bilirubin, 197

characterization of bacteria, 197

coprostanol, 198

microscopical examinations, 197

parasites, 197

urobilinogens and urobilins, 197-198

**Identification of saliva**:

alkaline phosphatase, 183-184

amylase: as basis of medicolegal test for saliva, 184-185

dyed-starch methods, 185-187

dyed-starch test papers, 187

anti-human saliva serum, 187-189

fluorescence of saliva stains, 189

microscopical methods, 189

nitrite, 183

salts and low MW compounds composition, 195

thiocyanate, 183

**Identification of semen**:

acid phosphatase: apparent polymorphism of seminal enzymes, 167-168

assay techniques, 162-163

description, 155

discovery, 155

immunogenicity of seminal enzymes, 168

independence of antigenic and catalytic sites, 168

as marker for seminal fluid, 155-157

molecular heterogeneity, 167-168

persistence in seminal stains, 162

persistence in vagina after semen deposition, 161-162

purification and properties of seminal enzyme, 166-168

quantitative assays in stains, 159-160

rocket electrophoresis with specific antibody, 171

seminal and vaginal enzyme relationship, 166

separation of SAP and VAP, 166

specificity of test, 157-159, 163-166

substrates for the enzyme, 162-163

tartrate inhibition of, 165-166

units of activity, 162-163, (table) 164

amino acids, 178

choline: detected chromatographically, 174-175

detected by crystal test, 172-173

chromatographic methods, citric acid, 175

spermine and choline, 174-175

composition of semen: enzymes, 180

(See also under specific enzyme names)

seminal plasma proteins, 179-180

sperm antigens, 179

table, 181

creatine phosphokinase, 175-176

crystal tests: Barberio test, 173-174

Florence test, 172-173

Niederland and Peltzer tests, 174

- Puranen's test, 174
- diamineoxidase, 177
- early chemical tests of historical interest, 149-150
- fluorescence of seminal stains, 178
- $\gamma$ -seminoprotein, 177
- immunological: anaphylaxis methods, 171-172
  - anti-human semen sera, 169-171
  - anti-p30, 180
  - anti-seminal acid phosphatase, 171
  - complement fixation test, 171
  - $\gamma$ -seminoprotein, 177
  - lactic dehydrogenase-X, 176
  - p30 protein, 180
- potato phytagglutinin inhibition, 178
- seminal fluid esterases, 176-177
- sperm cell esterases, 176-177
- spermatozoa: destruction of substratum, 151
  - examination of stains directly for, 151
  - histological staining of, 151-152
  - historical material, 150
  - morphology and its forensic implications, 154-155
  - persistence in vagina (see Identification of semen, spermatozoa, survival in vagina)
  - separation of cells from substrata, 150-151
  - survival in vagina, 152-154
  - transfer techniques, 151
- spermine: detected chromatographically, 174-175
  - detected by crystal test, 173-174
  - detected enzymatically, 178
  - detected by Fuchs-Tokuoka reaction, 178
- Identification of urine:**
  - chloride, 191
  - chromatographic methods, 194
  - composition of urine: chloride, 191
  - creatinine, 193
  - indican, 193
  - phosphate, 191
  - table, 195
  - urea, 193
  - creatinine: Jaffe test, 193
  - Sakaguchi test, 193
  - Salkowski test, 193
  - fluorescence of urine stains, 191
  - indican, 193
  - microscopical methods, 191
  - odor, 191
  - phosphate, 191
  - urea: crystal tests, 192
    - p*-dimethylaminobenzaldehyde reaction, 192
    - dimethylaminocinnamaldehyde (DMAC) reaction, 192-193
    - enzymatic test with urease, 192
    - xanthidrol reaction, 191-192
- Idiotypic**, 601
- IgA**, structure, 46
- IgD**, structure, 46
- IgE:**
  - as mediator of anaphylaxis, 56
  - structure, 46
- IgG**, structure, 46-47
- IgM**, structure, 46
- Ii system**, 389
- Iol** (see Inter- $\alpha$ -trypsin inhibitor)
- Immune response** (see Antibodies, formation)
- Immunity:**
  - cellular, 45
  - humoral, 45
- Immunodiffusion:**
  - double: description, 57-57
  - development of technique, 224-225
  - interpretation of precipitin patterns, 57-58, (illus.) 59
  - earliest observations, 224
  - single, 224
    - description, 57
    - linear, 57
    - radial, 57
- Immunoelectrophoresis:**
  - cross over, 62-63
    - in precipitation test for species determination, 225
  - crossed, 63, (illus.) 64
  - quantitative, 63-65
  - rocket electrophoresis: description, 63, (illus.) 64
    - in identification of semen with anti-seminal acid phosphatase, 171
  - and serum group proteins, 564, 566
  - of serum proteins, (illus.) 567
  - simple, 62
  - and species determination, 238
- Immunofixation electrophoresis:**
  - description, 63
  - and serum group protein typing, 566
- Immunoglobulins:**
  - classes of, 46, 48
  - genetic markers of (see Gm system, Km system, Am markers, Hv markers)
  - nomenclature, 46-48
  - properties of, 46, 48
  - structure (see Antibodies, structure)
- c1-Ina** (see c1-Activator)
- Inborn errors of metabolism**, 20
- Incomplete penetrance**, 30
- Indophenol oxidase** (see Superoxide dismutase)
- Inheritance:**
  - crossing over, 32-33, 35
  - independent assortment, 29-30, 33
  - linkage, 32
  - patterns in populations (see Population genetics)
  - pedigrees and pedigree symbols, 39, (illus.) 40-41
  - segregation, 27-28, 32
  - sex-linked, 33-38
    - dosage compensation, 34
    - X-chromosome inactivation, 34, 38
  - sex-related, 33-38
  - simple mendelian patterns, 27-30
- Inhibition of precipitation** (see Determination of species, immunological)
- Inhibition tests**, blood group substances in body fluids:
  - A<sub>1</sub> and A<sub>2</sub> cells in anti-A tests, 286
  - inhibitive titer, 285
  - techniques, 285-286
  - titration of body fluids, 285-286
- Inhibition-titration** (see ABO system, bloodstain grouping by inhibition, Holzer technique)
- Inter- $\alpha$ -trypsin inhibitor**, 595
- Iodine-starch reaction**, 184
- Ion-exchange chromatography** (see Chromatography)
- Iron-binding protein** (see Transferrin)
- Isoelectric focusing**, development of technique, 65
- Isoenzymes:**
  - content in blood, body fluids and tissues (see Genetic marker systems, content of proteins in blood body fluids and tissues)
  - development in fetuses and children (see Genetic marker systems, development in fetuses and children)
  - discovery of, 423
  - in hair roots, 637
  - molecular bases for, 423
  - polymorphic forms in saliva (see Saliva, polymorphic isoenzymes)
  - simultaneous typing of two or more systems, 432, 441-442, 452-453, 461, 475, 482, 493, 497, 508
- Isoprecipitins**, 611
- Isoprene**, 12

**Isotachopheresis**, 65

**Isotype**, 601

**Isozymes** (see Isoenzymes)

**Jay antigen** (see P system, Tj<sup>a</sup>)

**Jk** (see Kidd system)

**Kell system:**

antibodies, 371

application to disputed parentage testing, 371-372

bloodstain grouping, 372

complexities, 369-370

detectability of antigens in aging samples, 372

distribution of phenotypes in U.S. populations, 376-377

genetics, 370-371

Js (Sutter) antigens, 369

K and k antigens, 369

Kp antigens, 369

Kp<sup>c</sup> antigen identity with Levay, 370

numerical nomenclature, 370-371

relationship with chronic granulomatous disease (CGD), 370-371

**Ketoses** (see Carbohydrates)

**Kidd system**, 373-375

distribution of phenotypes in U.S. populations, 378-379

**Km system:**

application to disputed parentage testing, 608

factors and nomenclature, 607

markers, (table) 602

typing in bloodstains, 608-609

typing in body fluids and tissues, 609-610

typing methods, 607-608

**Koch, Robert**, 221

**L antigen** (see Lectin, Lotus antigen)

**LA** (see HLA system)

**Lactate dehydrogenase:**

genetic variation, 517

isoenzyme patterns, 125

isoenzyme patterns for identification of menstrual blood (see Identification of blood, menstrual blood)

as one of first discovered human isoenzymes, 423

reaction catalyzed by, 125

species determination by isoenzyme separation, 244

subunit structure, 125

subunit structure of isoenzymes, 423

X-isoenzyme for semen identification (see Identification of semen)

**Lacto-N-fucohexaose I**, 288

**Lacto-N-fucopentaose II**, 288

**Lactoyl-glutathione lyase** (see Glyoxalase I)

**S-Lactoyl-glutathione methylglyoxal lyase** (isomerizing) (see Glyoxalase I)

**Landsteiner, Karl:**

discovery of ABO blood groups, 261

Nobel laureate immunologist, 262

photo, 254

**Landsteiner-Richter test** (see ABO system, bloodstain grouping)

**LAP** (see Leucine aminopeptidase)

**Lattes, Leone**, 255

(See also Unit IX)

**Lattes procedure** (see ABO system, bloodstain grouping by isoagglutinin detection)

**Ld system** (see Serum lipoproteins)

**LDH** (see Lactate dehydrogenase)

**Lectin:**

anti-A: *Dolichos*, inhibition by secretor saliva, 282

*Phaseolus* inhibition by secretor saliva, 283

anti-B: *Evonymus*, 283, 305

anti-H: *Cystisus*, 273, 282-283

*Erythrina*, 282

*Laburnum*, 273, 282-283, 305

*Lotus*, 273, 282

*Psophocarpus*, 282

*Ulex*, 273, 282-283, 304

anti-M, *Iberis amara*, 338

anti-N: *Bauhinia*, 338

*Vicia gramineae*, 338

*Dolichos*: reacton with animal blood cells, 237

structural studies, 289

*Lotus*: antigen in saliva, 283

purification and biochemical properties, 283

structural studies, 289

**Les** (see Lewis system, in body fluids)

**Leucine aminopeptidase** (see Identification of blood, diagnosis of pregnancy from bloodstains)

**Leuco base**, 108

**Leuco compound** (see Leuco base)

**Leucocrystal violet** (see Catalytic tests, leucocrystal violet)

**Leucocyte:**

recovery from bloodstains, 630

(See also White blood cell, HLA system)

**Leucomalachite green** (see Catalytic tests, leucomalachite green)

**Lewis system:**

antigenic structures, 290, 291, 293

antisera, 331-333

assignment of gene locus symbols, 386

biochemical genetics, 290-293, 333

body fluid grouping, 319

in body fluids, 330

complexities, 330-331

discovery and development, 329

distribution of phenotypes in U.S. populations, 334

genetics, 333

genetics and relation to *Se/se* and *ABH*, 329-330

*Le<sup>c</sup>* and *Le<sup>d</sup>*, 331

red cell antigens, 330

relationship to ABO and secretor systems, 290-293

relationships of body fluid and red cell types, (table) 332

relationship to *Ii* antigens, 389

relationship of red cell Lewis type and secretor status, 329

relationship of secretor and Lewis genotypes to red cell and body fluid antigens, 295

stain typing of, 333

type 1 chain conversions to group substances, 293

type 2 chain conversions to group substances, 294

**Lipids:**

chemical definition, 7

structure and nomenclature, 7-11

**Lipoprotein** (see Serum lipoproteins)

**LISS** (see Low ionic strength solutions)

**Low ionic strength solutions**, enhancement of agglutination by, 51, 363

**Lowry method** (see Proteins, assay methods)

**Löw's papain**, 353

**Lp system** (see Serum lipoproteins)

**Luminol** (see Catalytic tests, luminol)

**Lutheran system**, 386-387

**Lyon hypothesis** (see Inheritance, sex-linked, X-chromosome inactivation)

$\alpha_2$ M (see  $\alpha_2$ -Macroglobulin)

$\alpha_2$ -Macroglobulin, 595

AL-M marker, 617

polymorphism, 617

Xm marker, 617

**Major histocompatibility complex** (see HLA system)

**Makate dehydrogenase**, 423

**Maltose**, 9

**May-Grünwald stain** (see Stains, histological)

**Meiosis**, 26, 31

**Melibiose**, 289

**Memory immune response** (see Antibodies, formation)

- Mendel, Gregor:**  
 contributions to classical genetics, 20  
 photo, 5
- Menstrual blood** (see Identification of blood, menstrual blood)
- Metchnikoff, Elie**, 221
- 4-Methylumbelliferyl phosphate** (see Acid phosphatase, substrates)
- M<sup>h</sup>** (see MNSs system, variants of M and N)
- MHC** (see HLA system)
- Michaelis-Menten kinetics**, 16–19
- Micrometry** (see Determination of species, micrometry)
- Microscopical methods for blood identification** (see Identification of blood, microscopical methods)
- Mitnberger antigens** (see MNSs system, associated antigens)
- Mitosis**, 26, 31
- Mixed agglutination:**  
 for ABO grouping of bloodstains (see ABO system, bloodstain grouping by mixed agglutination)  
 different meanings of the term, 52
- Mixed cell agglutination reaction (MCAR)**, 311–312
- M<sup>k</sup>** (see MNSs system, variants of M and N)
- MNSs system:**  
 antisera and lectins, 338  
 application to disputed parentage testing, 342–343  
 associated antigens, 338  
 biochemical genetics, 341–342  
 bloodstain MN grouping by fluorescent-labelled antibodies, 312  
 detectability of antigens in aging samples, 344, 345  
 distribution of phenotypes in U.S. populations, 346–347  
 genetics, 335–336  
 heterozygous advantage and MN, 338  
 linkage of MN and Ss, recombination and mutation, 335–337  
 MN antigens: amino acid sequence structures, 342–343  
   anti-N reaction with M cells, 340  
   anti-N reactions with M cells and stains, 344–345  
   bloodstain grouping by elution and mixed agglutination, 344  
   bloodstain grouping by inhibition, 343–344  
   chemical studies, 339–340  
   discovery, 335  
 Ss antigens: bloodstain grouping of, 345  
   discovery, 335  
 U antigen, 337  
 variants of M and N, 337–338  
 Vw typing in bloodstains, 346
- Molecular sieving** (see Chromatography, gel filtration)
- Morgan, Thomas Hunt:**  
 Nobel laureate in genetics, 20  
 photo, 5
- Morgan, as genetic map distance unit**, 33
- Mucins**, 339
- Mucoids**, 339
- Mucopolysaccharides**, 339
- "Multisystem" isoenzyme typing** (see Isoenzymes, simultaneous typing of two or more systems)
- Mutation**, 38
- M<sup>r</sup>** (see MNSs system, variants of M and N)
- Myeloma proteins**, 604
- Myokinase** (see Adenylate kinase)
- N-Acetyl-neuraminic acid**, structure, 10
- NADH-methemoglobin reductase** (see Diaphorases)
- Naphthanil Diazo Blue B**, 157, 159
- Naphthanil Diazo Red AL**, 157, 158
- Naphthanil Diazo Red RC**, 157, 159
- Naphthol AS phosphates** (see Acid phosphatase, substrates)
- Naphthol yellow S**, 174
- Naphthylphosphates** (see Acid phosphatase, substrates)
- N-acetyl-Neuraminic acid**, structure, 10
- Nitrite** (see Identification of saliva)
- p-Nitrophenyl phosphate** (see Acid phosphatase, substrates)
- nL** (see Lewis system, in body fluids)
- Nongenetic markers:**  
 antibodies in blood, 669–670  
 classes of and description, 669  
 drugs in bloodstains, 670  
 hepatitis antigens, 670–671  
 plasma ions and metabolites, 670  
 serum protein profiling, 671
- Nucleic acids** (see DNA, RNA)
- Nucleosides**, 21, 23
- Nucleotides**, 21, 24
- Nuttall, G.H.F.**, 222, 241
- Ogata-Matuhasi phenomenon**, 278
- O<sub>1</sub>** (see ABO system, para-Bombay phenotypes)
- Or** (see  $\alpha_1$ -Acid glycoprotein)
- Orfila, M.J.B.:**  
 biography, 74  
 early investigations on blood identification, 74–75  
 photo (see Unit IX)
- Orosomucoid** (see  $\alpha_1$ -Acid glycoprotein)
- Ortho-dianisidine** (see Catalytic tests, o-dianisidine)
- Ortho-tolidine** (see Catalytic tests, o-tolidine)
- Ortho-toluidine** (see Catalytic tests, o-toluidine)
- Orthophosphoric-monoester phosphohydrolase** (alkaline optimum) (see Alkaline phosphatase)
- Ouchterlony, Ö.**, 224–225
- P system:**  
 application to disputed parentage testing, 385  
 biochemistry and biochemical genetics, 383–385, 386  
 bloodstain grouping, 385  
 discovery and development, 381  
 Q antigen, 383  
 serology, 381–383  
 Tj<sup>a</sup> antigen, 381–382
- Pa** (see Saliva, polymorphic protein systems)
- $\alpha_1$ -PAG** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- PAPP** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Para-phenylenediamine** (see Catalytic tests, p-phenylenediamine)
- Pb** (see Saliva, polymorphic protein systems)
- P.C.E.** (see Cholinesterases, serum pseudocholinesterase)
- Pedigree** (see Inheritance)
- Penney antigen** (see Kell system)
- PEP** (see Peptidases)
- Pepsinogens**, 517–518
- Peptidases:**  
 application of PEPA polymorphism to disputed parentage testing, 507  
 biochemical properties of isoenzymes, 507  
 detection reactions in typing media and assay, 504, 506  
 distribution of PEPA phenotypes in U.S. populations, 508  
 electrophoretic patterns of PEPA phenotypes, 508  
 genetic variation of PEP A, B, C, D, 506–507  
 grouping PEPA in bloodstains, 507–508  
 grouping PEPA in semen, 508  
 linkage relations and chromosomal localization of PEP loci, 507  
 multiple genetic loci determining isoenzymes, 503–504  
 red cell and tissue isoenzymes, 503–504  
 relative electrophoretic mobilities of different isoenzymes, 504  
 substrate specificities of different isoenzymes, 505  
 typing PEPA simultaneously with other isoenzyme systems, 508
- Perhydrocyclopentanophenanthrene**, 10  
 (See also Steroids)
- Periodic acid**, destruction of blood group receptors, 308
- Peroxidase:**  
 activity of hemoglobin (see Catalytic tests, peroxidase activity)

- general reaction (see Catalytic tests, peroxidase reaction)
- as one of first isoenzymes, 423
- salivary polymorphic (see Saliva, polymorphic isoenzymes)
- Peroxide** (see Catalytic tests, peroxide)
- Pg** (see Pepsinogens)
- PGD** (see 6-Phosphogluconate dehydrogenase)
- PGM** (see Phosphoglucomutase)
- PGP** (see Phosphoglycolate phosphatase)
- Ph** (see Saliva, polymorphic protein systems)
- Phenolphthalein phosphate** (see Acid phosphatase, substrates)
- Phenolphthalin test** (see Catalytic tests, phenolphthalin)
- Phenotype**, 27
- p-Phenylenediamine** (see Catalytic tests, p-phenylenediamine)
- Phenylketonuria**, 20-21
- Phenylphosphate** (see Acid phosphatase, substrates)
- Phosphate**, colorimetric determination of, 162
- Phosphatidic acid**, structure, 9
- Phosphatidyl derivative**, structure, 10
- 6-Phospho-D-gluconate:NADP<sup>+</sup>-2-oxidoreductase** (decarboxylating) (see 6-Phosphogluconate dehydrogenase)
- Phosphoglucomutase**:
  - application to disputed parentage testing, 430
  - biochemical properties, 427, 429
  - biochemical studies on the isoenzymes, 429-430
  - detectability of isoenzymes in aging blood and bloodstains, 432-433
  - detection reactions in typing media, 431
  - distribution of phenotypes in U.S. populations, 436-437
  - effect of PMS concentration in detection reaction mixture, 432
  - electrophoretic patterns of phenotypes, 428
  - grouping in bloodstains, 431-432
  - grouping in semen, vaginal secretions and other tissues, 433-435
  - linkage relationships of *PGM* loci, 427
  - PGM*, alleles, 425-426
  - PGM*, alleles, 426-427
  - PGM*, alleles, 427
  - PGM*, alleles by isoelectric focusing, 426
  - PGM*, silent alleles, 425-426
  - polymorphism, 425-426
  - problems with bloodstain grouping, 433
  - reaction mechanism, 430
  - recognition, 425
  - species determination by isoenzyme separation, 244
  - subtyping of *PGM*, isoenzymes, 426, 432
  - typing simultaneously with other isoenzyme systems, 432
- 6-Phosphogluconate dehydrogenase**:
  - application to disputed parentage, 492
  - biochemical properties of isoenzymes, 492
  - distribution of phenotypes in U.S. populations, 494
  - genetic variation and polymorphism: classes of genetic variants, 488
  - deficient activity variants and silent alleles, 490
  - nomenclature, 490-492
  - normal activity variants, 488-490
  - properties of variants, (table) 491
  - grouping in bloodstains, 492-493
  - grouping in body fluids and tissues, 493
  - inactivation of enzyme by NADP and red cell stroma, 492
  - linkage relations of *PGD*, 492
  - recognition, 488
  - typing simultaneously with other isoenzyme systems, 493
- Phosphoglycerides** (see Lipids)
- Phosphoglycolate phosphatase**, 520
- Phosphohexose isomerase** (see Glucose phosphate isomerase)
- Phytagglutinins**, species determination using, 237
  - (See also Lectins)
- Phytoprecipitins** (see Determination of species, immunological)
- PI** (see  $\alpha_1$ -Antitrypsin)
- PL** (see Alkaline phosphatase, placental)
- Plasma ions and metabolites** (see Nongenetic markers)
- Pm** (see Saliva, polymorphic protein systems)
- Polyacrylamide gel electrophoresis** (see Electrophoresis)
- Polymorphic proteins in hair** (see Hair)
- Polymorphic proteins in saliva** (see Saliva, polymorphic protein systems)
- Polymorphism**:
  - as basis for discrimination in populations, 39
  - definition, 38-39
  - as population genetic phenomenon, 39
- Population**, frequencies of genetic markers in a (See United States populations, frequencies of distribution of genetic markers)
- Population genetics**:
  - Chi-square goodness-of-fit test, 40-41
  - discrimination index, 42
  - Hardy-Weinberg equilibrium, 39-40
  - probability of identity, 42
  - significance (usefulness) of genetic marker systems, 41-43
- Porphyrins**:
  - heme and hematin compounds, 77-79
  - structure, types, nomenclature, 77-78
- Pr** (see Saliva, polymorphic protein systems)
- Pr proteins**, 595
- Precipitation**:
  - anti-bacterial antibodies, 221
  - antibodies against blood and body fluids, 221
  - antibodies against milk proteins, 221
  - antibodies against ovalbumin, 221
  - as antigen-antibody reaction
  - antitoxin antibodies, 221
  - mechanism, 53
  - optimization of reactant concentrations, 227
  - preparation of precipitating antisera, 223-224
  - quantitative procedures, 53-54
- Precipitation-inhibition** (see Determination of species, immunological)
- Precipitin test**:
  - for determination of species of blood (see Determination of species, immunological)
  - for identification of saliva (see Identification of saliva, anti-human saliva serum)
  - for identification of semen (see Identification of semen, immunological)
- Precipitins**, antibodies as, 49
- Pregnancy**, forensic diagnosis of (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Pregnancy-associated  $\alpha_2$ -glycoproteins** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Pregnancy-associated plasma proteins** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Pregnancy-associated proteins** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Pregnancy hormones** (see Identification of blood, diagnosis of pregnancy from bloodstains)
- Pregnancy zone protein** (see identification of blood, diagnosis of pregnancy from bloodstains)
- Primary immune response** (see Antibodies, formation)
- Probability of exclusion** (see Disputed parentage testing)
- Probability of identity** (see Population genetics)
- Procion Brilliant Red M2BS starch**, 185
- Profiling of blood components** (see Nongenetic markers)
- Prokop, Otto**, 255
- Prostatic acid phosphatase** (see Identification of semen, acid phosphatase)
- Protectins**, anti-A from snails, 283
- Protein synthesis**, 24-25, 29
- Proteins**:
  - assay methods, 15
  - estimation of concentration in bloodstain extracts (see Determination of species, immunological)
  - forces involved in structure, 12-14
  - primary structure, 12
  - purification, 14-15
  - quaternary structure, 14
  - secondary structure, 12



- specific activity, 15
- tertiary structure, 12
- Protoporphyrin IX**, 80
- Pseudocholinesterase** (see Cholinesterases)
- Ptyalin** (see Amylases)
- Purine bases**, 21–22
- Pyranoses** (see Carbohydrates)
- Pyrimidine bases**, 21–22
- Q antigen** (see P system)
- Quinacrine diHCl**, 666
- Race, R.R.**, 255
- Racial origin of blood determined by immunological technique** (historical), 223
- Radioimmunoassay**:
  - for allergen antibodies in bloodstains, 670
  - description of technique, 54
  - for determination of drugs in bloodstains, 670
  - in sex hormone level measurements, 668
- Raspail, F.V.**, 74
- $\alpha$  Ratio** (see Age of bloodstains, determination of)
- Rautenberg antigen** (see Kell system)
- Reagin** (see IgE)
- Red blood cell**:
  - antigen detection on, using sensitized cells, 277
  - content in blood, 545
  - effect of formalin treatment on ABO antigens, 312
  - measurements of cells, tables, 218–220
  - measurements of cells reconstituted from bloodstains, 215–217
  - “reconstitution” from bloodstains, 216
    - (See also Identification of blood, microscopical methods)
  - recovery from cryopreservation in DMSO on post-mortem blood by reversible agglomeration, 312
  - sensitized, 50
  - solutions for “reconstituting” from bloodstains, 95
- Regan isoenzymes**, 510
  - (See also Alkaline phosphatase, in serum of cancer patients)
- Remazol Blue R starch**, 185
- Reversible agglomeration**, 312
- Rg<sup>a</sup>** (see Complement components, C4)
- Rh system**:
  - application to disputed parentage testing, 361–362
  - biochemical genetics, 361
  - bloodstain grouping and agglutination enhancement techniques, 363
  - bloodstain grouping by elution, 362–363
  - bloodstain grouping by inhibition, 362
  - bloodstain grouping interpretation, 363–364
  - C<sup>w</sup> antigen, 353–354
  - compound or complex antigens and antisera, 354–355
  - D<sup>u</sup> antigen, 353
  - detectability of antigens in aging samples, 362–363
  - discovery and development, 349–350
  - distributions of phenotypes in U.S. populations, 366–367
  - f (hr) antigen, 354
  - G antigen, 355
  - genes and gene complexes, (table) 351
  - genetics and inheritance patterns, (table) 352, 357
  - incomplete anti-D, 352
  - isolation and purification of Rh antigens, 359–360
  - LW antigen, 355–356
  - nomenclature, 350–352
  - number of Rh antigens on red cells, 358
  - numerical nomenclature system, 357–358, 359
  - phenotypes and genotypes, 352
  - properties of purified Rh antigens, 360–361
  - relationship of antigens to red cell membrane, 359
  - Rh<sub>null</sub>, 356
  - subdivisions of D(RH<sub>0</sub>), 353
  - suppressions, deletions and modifiers, 356
  - variations in C (rh<sup>+</sup>) antigen, 353–354
  - variations in E (rh<sup>+</sup>) and e (hr<sup>+</sup>) antigens, 354
- Rhodamine B** (see Catalytic tests, rhodamine B)
- RIA** (see Radioimmunoassay)
- Richet, Charles R.**, 221
- RNA**:
  - messenger, 23
  - ribosomal, 23
  - structure, 21–22
  - transfer, 23–24, 28
- RO2-0683**, 468–469
  - (See also Cholinesterases)
- Rocket electrophoresis** (see Immunoelectrophoresis)
- Rodgers** (see Complement components, C4)
- R-type precipitating antisera**, 53–54
- Sal** (see Saliva, polymorphic protein systems)
- Saliva**:
  - ABO antibodies in, 273–274
  - ABO antigens in (see Secretor system, ABH substances in body fluids)
  - antigen detected by *Lotus* lectin, 283
  - identification (see Identification of saliva)
  - polymorphic isoenzymes: acid phosphatase (Sap), 634
    - amylase (AMY), 510–511
    - application to disputed parentage, 635
    - esterases (Set), 634
    - glucose-6-phosphate dehydrogenase (Sgd), 634
    - parotid peroxidase (SAPX), 634
    - salivary esterase typing in stains, 635
  - polymorphic protein systems: major parotid glycoprotein (GI), 633
    - Pa, 631–632
    - Pb, 632–633
    - Pm and Ph, 633
    - Pr and Db, 632
    - Sal I and Sal II, 633–634
    - summary of salivary polymorphisms, 631
    - typing procedures, 634–635
  - protein components by immunoelectrophoresis, 188–189
- Sanger, Ruth**, 255
- Sap** (see Saliva, polymorphic isoenzymes)
- SAP** (see Acid phosphatase, seminal)
- SAPX** (see Saliva, polymorphic isoenzymes)
- Schiff, Fritz**, 254
- Schutzstoff** (see Complement)
- Scianna system**, 391
- SD [Serologically Defined]** (see HLA system)
- SD [Sperm Diaphorase]** (see Diaphorases)
- Sd<sup>a</sup>** (see Sid and Cad)
- Se** (see Secretor system)
- Secondary immune response** (see Antibodies, formation)
- Secretor system**:
  - ABH substances in body fluids: A secretor semen and snail anti-A, 284–285
    - A substance variation within A subgroups, 282
  - aberrant secretors, 282–283
  - blood group substance destroying enzyme in saliva, 286
  - Dolichos* and *Phaseolus* lectins, 283
  - earlier studies, 280–281
  - inhibition techniques for determination of, 285–286
  - “molecular weight polymorphism” of, 319–320
  - newborn salivas, 284
  - precipitation reactions, 283
  - quantitative studies with saliva, 282–283
  - quantitative studies with semen, 284
  - recognition of, 280
  - saliva, 282–284
  - saliva preparation for testing, 286
  - salivary gland contributions to salivary substances, 283–284

- semen, 284-285
- sperm cells, 284
- variations in H level with different anti-H, 282-283
- application to disputed parentage testing, 297, 313
- biochemical genetics, 290-293
- distribution of phenotypes in U.S. populations, 328
- inheritance, 281-282
- relationship of secretor and Lewis genotypes to red cell and body fluid antigens, 295
- relationship to ABO and Lewis, 290-293
- secretor gene symbols, 282
- Semen:**
  - ABH substances in (see Secretor system, ABH substances in body fluids)
  - ABO antibodies in, 273
  - composition of, salts and low MW compounds, 195
  - (See also Identification of semen, composition of semen)
  - content of genetic marker system proteins in (see Genetic marker systems, content of proteins in blood, body fluids and tissues)
  - enzymes (see Identification of semen, composition of semen)
  - genetic markers in (see Body fluids and tissues)
  - genetic marker typing in (see Body fluids and tissues)
  - identification (see Identification of semen)
  - phosphoglucomutase grouping of, 433-435
  - proteins of (see Identification of semen, composition of semen)
- Semen crystal tests** (see Identification of semen, crystal tests)
- Seminal acid phosphatase** (see Identification of semen, acid phosphatase)
- Sensibilisatrice** (see Hemolysins)
- Sensitized particles:**
  - colloidon particles, 231-233
  - latex particles, 233
  - pregnancy test based on, 233
- Separation of blood from debris** (see Chromatographic methods)
- Serum group systems**, concentration ranges of proteins in serum, 563-564
- (See also Serum proteins)
- Serum lipoproteins:**
  - Ag system: application to disputed parentage testing, 613
  - recognition and polymorphism, 611-613
  - relationship of studies on to Australia antigen, 611, 670
  - classification and properties, 611
  - Ld system, 613
  - Lp system, 613-614
- Serum proteins:**
  - antigenicity of heat denatured, 226
  - basis of genetic variation in, 564
  - electrophoretic and immunoelectrophoretic behavior of, (illus.) 567
  - as genetic markers, 563-564
  - methods of separation and characterization, 564, 566
  - nature and classification of, 563-564
  - nomenclature and properties summary, 565
  - profiles, related to bloodstain age (see Age of bloodstains, determination of)
  - profiling of, 671
  - (See also Nongenetic markers)
  - (See also Serum group systems)
- Serum sickness**, 56
- Serum ions and metabolites** (see Nongenetic markers)
- Set** (see Saliva, polymorphic isoenzymes)
- Sex chromatin:**
  - in cells and tissues as sex of origin indicator, 666
  - description and occurrence, 665
  - as related to X-chromosome inactivation, 34, 38, 665
  - (See also Inheritance, sex-linked, X-chromosome inactivation)
  - as sex of origin indicator in bloodstains, 665-666
- Sex hormone level measurements**, 668
- Sex of origin:**
  - of blood by serum protein profiling, 671
  - cytological methods: F-bodies, 666-668
  - sex chromatin, 665-666
  - by determination of sex hormones, 668
- Sgd** (see Saliva, polymorphic isoenzymes)
- Sialic acid** (see *N-acetyl*-Neuraminic acid)
- Sid and Cad**, 390-391
- Siderophilin** (see Transferrin)
- Siracusa, Vittorio** (see Unit IX)
- 6-Phosphogluconate dehydrogenase** (see at Phosphogluconate dehydrogenase)
- S-Lactoyl-glutathione methylglyoxal lyase** (isomerizing) (see Glyoxalase I)
- Sm** (see Scianna system)
- SOD** (see Superoxide dismutase)
- Solanidine**, 465
- Solanine**, 465
- Species of origin** (see Determination of species)
- Sperm diaphorase** (see Diaphorases)
- Spermatozoa:**
  - detection as means of seminal stain identification (see Identification of semen, spermatozoa)
  - DIA**, isoenzymes in, 519-520
  - discovery, 150
  - morphology (see Identification of semen, spermatozoa)
  - structural (cytological) profiling (see Identification of semen, spermatozoa)
- Spermine**, 174
- (See also Identification of semen)
- Sphingolipids** (see Lipids)
- Sphingomyelin structure**, 10
- Sphingosine structure**, 10
- Stains, histological:**
  - Biebrich scarlet, 96, 100
  - for blood cells in bloodstains (see Identification of blood, microscopical methods)
  - CI [colour index], 97
  - eosin, 97, 100
  - Feulgen, 97
  - general, 97
  - Giemsa, 97
  - hematoxylin, 97, 100
  - May-Grünwald, 97
  - preparation of Graham, 96
  - for spermatozoa in seminal stains (see Identification of semen, spermatozoa)
  - table of, 96-99
- Starch:**
  - amylpectin, 187, 188
  - amylose, 187, 188
  - dye-linked as substrate for amylase, 185-187
- Starch gel electrophoresis** (see Electrophoresis)
- Starch-iodine reaction**, 184
- Steroids:**
  - cholesterol, 11
  - as class of lipids, 9
  - estradiol, 12
  - steroid nucleus structure, 10
  - testosterone, 11
- S<sup>u</sup>** (see MNSs system, U antigen)
- Subgroups of A** (see ABO system)
- Succinylcholine**, 464
- (See also Cholinesterases)
- Sugars** (see Carbohydrates)
- Superoxide dismutase**, 512
- Sutherland, William Dunbar**, 74
- Sutter antigens** (see Kell system)
- Suxamethonium** (see Succinylcholine)
- Sweat:**
  - ABO grouping (see ABO system, body fluid and tissue grouping)
  - composition, 195
  - identification, 199
- Sydney**, 427

- T antigen:**  
in the Hübener-Thomsen-Friedenreich phenomenon, 339  
as original designation of Le<sup>a</sup>, 329
- T-cells**, 45
- Takayama, Masao**, 86  
(See also Unit IX)
- Tanned red cells:**  
absorption of proteins by, 52, 229–331  
closely related species differentiation and, 239
- Taxonomic serology** (see Determination of species, immunological)
- TBG** (see Thyroxine binding  $\alpha$ -globulin)
- TBPA** (see Thyroxine binding prealbumin)
- Tc** (see Transcobalamin)
- Tears:**  
ABO antibodies in, 274  
identification of, 199  
specific protein in, 199
- Teeth:**  
ABO grouping of tissue from (see ABO system, body fluid and tissue grouping)  
phosphoglucomutase grouping in tissues of, 435  
(See also Body fluids and tissues)
- Teichmann, L.**, 80  
(See also Unit IX)
- Testosterone**, 11, 668
- Tetramethyl benzidine** (see Catalytic tests, tetramethyl benzidine)
- Tetrazolium oxidase** (see Superoxide dismutase)
- Tf** (see Transferrin)
- Thin starch gels for electrophoretic isoenzyme typing**, 431
- Thiocyanate** (see Identification of saliva)
- Thomsen phenomenon**, 339
- Thomsen-Friedenreich antigen**, 339
- Thymolphthalein phosphate** (see Acid phosphatase, substrates)
- Thyroxine binding  $\alpha$ -globulin**, 619–620
- Thyroxine binding prealbumin**, 619
- Titer:**  
of agglutinating antiserum, 53  
of precipitating antiserum, 53
- Titration-inhibition** (see ABO system, bloodstain grouping by inhibition, Hirsfeld and Amzel-Kind technique)
- Tj<sup>a</sup> antigen** (see P system)
- o*-Tolidine** (see Catalytic tests, *o*-tolidine)
- o*-Toluidine** (see Catalytic tests, *o*-toluidine)
- Transcobalamin**, 619
- Transferrin:**  
application to disputed parentage testing, 593  
in body fluids and tissues, 593  
distribution of phenotypes in U.S. populations, 594  
electrophoretic patterns of variant gene products, 590  
genetic variation and polymorphism, 589–590  
nomenclature of variants, 590  
recognition of, 589  
structure and biochemical properties, 592  
subtypes of Tf C, 590  
typing in bloodstains, 593  
variants arranged according to electrophoretic mobility, 591
- Triglyceride structure**, 9  
(See also Lipids)
- Triple bonded agglutination technique**, 311
- Uhlenhuth, Paul**, 221–222  
(See also Unit IX)
- Ultracentrifugation:**  
as method for estimating protein purity and MW, 16  
as protein purification technique, 15
- Ultraviolet (280/260) protein assay** (see Proteins, assay methods)
- UMPK** (see Uridine monophosphate kinase)
- United States populations**, frequencies of distribution of genetic marker phenotypes:
- ABO system, 324–327  
adenosine deaminase system, 462  
adenylate kinase system, 443  
 $\alpha$ -antitrypsin, 599  
carbonic anhydrase II system, 482  
cholinesterase variants, 476–477  
Duffy system, 378–379  
erythrocyte acid phosphatase system, 454–455  
esterase D system, 476–477  
galactose-1-phosphate uridylyl transferase variants, 514–515  
glucose-6-phosphate dehydrogenase system, 489  
glutamic-pyruvic transaminase system, 502  
glyoxalase I system, 497–498  
Gm and Km, 610  
group specific component, 586–587  
haptoglobin, 579–580  
Hb variants, 560–561  
Kell system, 376–377  
Kidd system, 378–379  
Lewis system, 334  
MNSs system, 346–347  
Peptidase A system, 508  
phosphoglucomutase system, 436–437  
6-phosphogluconate dehydrogenase system, 494  
Rh system, 366–367  
secretor system, 328  
transferrin, 594
- Units:**  
of acid phosphatase activity (see Acid phosphatase, units of activity)  
of amylase activity (see Amylases, units of activity)
- Urea** (see Identification of urine)
- Urease** (see Identification of urine)
- Uridine monophosphate kinase:**  
polymorphism, 518  
species determination by isoenzyme separation, 244
- Urine:**  
ABO grouping (see ABO system, body fluid and tissue grouping)  
composition (see Identification of urine, composition of urine)  
identification (see Identification of urine)  
U.S. populations (see United States populations)
- Vaginal acid phosphatase** (see Acid phosphatase, vaginal)
- Vaginal secretions:**  
ABO antibodies in, 274  
cervical mucus, 169  
composition of, 168–169  
enzymes and proteins in, 169  
epithelial cells: glycogen content of, 121–122, 168  
staining with iodine, 121  
identification of, 168–169  
intravaginal pH, 168–169  
phosphoglucomutase grouping of, 433–435  
relationship of pH, vaginal flora and glycogen in epithelial cells, 168–169  
vaginal flora, 168–169  
vaginal infections, 169
- van Deen's test** (see Catalytic tests, guaiacum)
- VAP** (see Acid phosphatase, vaginal)
- Variable expressivity**, 30
- Vitamin B<sub>12</sub> binding protein** (see Transcobalamin)
- Vitamin D binding protein** (see Group specific component)
- von Behring, Emil A.**, 221
- White blood cell**, identification in stains (see Identification of blood, microscopical methods)
- White patch enzyme** (see Superoxide dismutase)
- Wiener, Alexander S.**, 254
- Wilson's disease**, 619
- Wright system**, 391

$\alpha_1$ -X (see Antichymotrypsin)

Xh (see Identification of blood, diagnosis of pregnancy from blood-stains)

Xm (see  $\alpha_2$ -Macroglobulin)

Y-bodies (see F-bodies)

Yt system, 390

Zeta potential (see Agglutination, mechanism)

Zone phenomena (see Antigen-antibody reactions)

Zwischenferment (see Glucose-6-phosphate dehydrogenase)

Zymogram, 423